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2 Introduction 
According to the Global Burden of Disease analysis of the World Health Organization, 
cardiovascular diseases are the most common causes of death in industrialized 
societies (World Health Organization, 2008). Among this class of diseases, 
atherosclerosis is characterized by the formation of atheromatous plaques in the 
arterial wall that further may lead to medical complications such as myocardial 
infarction or stroke (Glass et al., 2001; Libby et al., 2011). Atherosclerosis has been 
subject to intense investigation but its pathomechanisms are not yet fully understood. 
Atherosclerosis is a multifactorial disease and both, genetic and environmental 
influences, like smoking or a high-fat and cholesterol diet, contribute to the risk for this 
disease (Glass et al., 2001; Moore et al., 2011). 
2.1 Development of atherosclerosis 
In general, atherogenesis occurs in several stages as schematized in figure 1. 
Inflammation at sites of the arterial wall contributes to the initiation of the development 
of lesions or plaques within the vascular lumen (Ross, 1999). This narrows the arteries 
and further reduces their flexibility, which in turn leads to a reduced supply with 
oxygen-rich blood to vital organs (Watkins et al., 2006). Acute clinical complications 
come up when plaque formation consistently continues, as the risk of a plaque rupture 
increases. Formation of a thrombus raises the danger for myocardial infarction or 
stroke (Libby et al., 2011). 
Disturbed laminar flow in arteries, which often occurs at arterial branch sites, 
predominantly facilitates atherosclerotic progression as shear stresses of blood flow 
decrease and turbulences increase (Ross, 1999; Moore et al., 2011). 
The accumulation of apolipoprotein B-containing lipoproteins (such as low-density 
lipoprotein, LDL) in the subendothelial space results in endothelial dysfunction and 
together with inflammation, these events represent the initial step (figure 1A) in 
atherosclerosis (Ross, 1999). Overlying endothelial cells secrete chemokines and 
thereby recruit monocytes and T lymphocytes, express adhesion molecules and 
increase their permeability in response to inflammatory stimuli (Glass et al., 2001). 
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Figure 1: Stages of atherosclerosis 
Endothelial dysfunction (A); Formation of the fatty streak (B); advanced complicated lesion formation 
(C); unstable fibrous plaque (D). Figures adapted from Ross, 1999 
 
Adhesion of monocytes to the endothelium allows their entry in the subendothelial 
space and thereafter, macrophage-colony stimulating factor (M-CSF) effects their 
differentiation into macrophages. Macrophages acquire several functions during 
differentiation. The expression of scavenger receptors and toll-like receptors is 
upregulated and thus, the ability of macrophages to internalize apoptotic cell fragments 
and modified LDL particles is increased (reviewed by Pello et al., 2011). However, little 
is known about the regulation of the cholesterol efflux transporters during macrophage 
differentiation. 
Modified forms of LDL are taken up by intimal macrophages and this process leads to 
the formation of so called foam cells. Foam cells are characterized by massive 
intracellular accumulation of cholesteryl esters and they are the main component of the 
fatty streak (figure 1B) and hence, they are characteristic for early atherosclerotic 
lesions (Libby et al., 2011). With further progression of atherosclerosis, smooth muscle 
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cells (SMCs) and T-cells migrate to the intima and leukocytes invade the 
subendothelial space. SMCs in the intima produce extracellular matrix proteins, which 
increase the volume of the lesion. A fibrous cap, which covers the atheromata is 
formed (figure 1C). The cap represents a boundary between lesion and lumen and 
may be considered to be a response to the injury of the endothelium (Ross, 1999). 
However, with atherosclerosis progression, monocytes continue to immigrate into the 
intima. Due to prolonged endoplasmic reticulum stress and other stimuli, macrophages 
undergo apoptosis (Moore et al., 2011). A necrotic core (figure 1C) develops as result 
of apoptosis of lesional macrophages and their ineffective phagocytosis. The necrotic 
core contributes to physical stress on the fibrous cap and may initiate thrombus 
formation since it contributes to further inflammation. The fibrous cap undergoes 
changes due to macrophage-derived matrix metalloproteinases, which degrade the 
extracellular matrix and other proteolytic enzymes (Moore et al., 2011). Thus, the 
fibrous cap becomes instable, which in turn increases the probability of a rupture 
(figure 1D). When the plaque ruptures, plaque material gets exposed to the lumen. 
Consequently, the coagulation cascade is initiated, platelets aggregate at the rupture 
site and a thrombus forms (for reviews see Ross, 1999; Glass et al., 2001; Libby et al., 
2011; Moore et al., 2011). 
2.2 Cholesterol metabolism 
Cholesterol is an important component of animal cells which plays many roles, among 
them providing rigidity to cell membranes, serving as precursor molecule for steroid 
hormones or bile acids (Maxfield et al., 2010) and as a component of signaling 
pathways (Incardona et al., 2000). Cholesterol metabolism is tightly regulated and 
dysregulation of cholesterol homeostasis is associated with diseases such as 
atherosclerosis (Glass et al., 2001). 
The synthesis of cholesterol proceeds from acetyl-CoA through many enzymatic 
reactions (Sato et al., 1995) with HMG-CoA (hydroxymethylglutaryl-Coenzyme A) 
reductase as rate limiting enzyme. Since this process is very energy consuming, cells 
retrieve cholesterol from the circulation by uptake of LDL via the LDL-receptor, which is 
located on the plasma membrane (Goldstein et al., 1977). Tight control of the 
intracellular cholesterol level is a prerequisite for maintaining cholesterol homeostasis. 
When the intracellular cholesterol concentration is low, sterol regulatory element 
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binding-proteins (SREBP) are activated, move from the cytosol to the nucleus and 
initiate transcription of genes responsible for cholesterol synthesis (HMG-CoA 
reductase) and uptake (LDL-receptor). In case of a cholesterol excess within the cell, 
HMG-CoA reductase activity is reduced and LDL-receptor expression declines 
(Goldstein et al., 2006). Furthermore, oxysterols are produced which bind to LXR (liver 
x receptor), thereby initiating heterodimerization of LXR with RXR (retinoid x receptor). 
This LXR/RXR complex activates expression of genes involved in cholesterol efflux 
(Tall, 2008). 
2.3 Reverse cholesterol transport and cholesterol efflux from 
macrophages 
The process of returning cholesterol from the periphery to the liver for excretion is 
known as reverse cholesterol transport (RCT). As described above (cpt. 2.2), cells 
retrieve cholesterol through the uptake of lipoproteins or de novo synthesis and cellular 
cholesterol homeostasis is strictly regulated. Peripheral cells, including vascular 
macrophages, are unable to degrade excess free cholesterol, which is toxic for them. 
Therefore, the mechanism used to avoid accumulation of surplus free cholesterol 
within cells is RCT (Francis et al., 1999). 
High density lipoprotein (HDL) is the key molecule in RCT and hence, it makes an 
important contribution to atheroprotection. The process of reverse cholesterol transport 
from macrophages is dependent on adenosine triphosphate (ATP) binding cassette 
transporters, mainly ABCA1 and ABCG1 (Tall, 2008). Efflux of cholesterol and 
phospholipids from macrophages to lipid poor apoA-I, which represents nacent HDL, 
occurs via ABCA1 on the cell membrane, while mature HDL requires attachment to 
ABCG1 to accept cholesterol (Yvan-Charvet et al., 2009). Furthermore, ABCA1-
mediated cholesterol efflux initiates the maturation of HDL by addition of lipids to apoA-
I and hence, ABCA1 and ABCG1 act synergistically, with ABCA1 generating nascent 
HDL particles which then further may serve as substrates for cholesterol efflux via 
ABCG1 (Gelissen et al., 2006). The enzyme lecitin-cholesterol acyltransferase (LCAT) 
is bound to the surface of HDL and is responsible for esterification of free cholesterol. 
Cholesterol esters are more hydrophobic than free cholesterol and therefore, 
cholesterol esters are transferred to the core of the HDL particle (Fielding et al., 1995). 
After loading, HDL travels via the blood stream to the liver where it binds preferably to 
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the scavenger receptor class B type I (SR-BI) for release of cholesterol and 
phospholipids (Valacchi et al., 2011).  
Besides ABCA1 and ABCG1, other molecules are also involved in cholesterol efflux 
from macrophages. One of them is SR-BI, which is an ubiquitous receptor and hence, 
also present on macrophages. There, it contributes to the efflux of free cholesterol 
from macrophages. SR-BI, however, is a bidirectional transporter and can also 
promote uptake of cholesterol and therefore its importance in macrophage RCT 
remains questionable (Valacchi et al., 2011; Cuchel et al., 2006). 
The main cause for foam cell formation is an imbalance between cholesterol efflux and 
extensive uptake of modified LDLs (Rader et al., 2005; Moore et al., 2006) as 
described in the next chapter. The mechanism of macrophage RCT is not efficient 
enough to compensate for this excessive cholesterol uptake. 
2.4 Modification of Low-Density Lipoproteins 
LDL is a macromolecule, consisting of phospholipids, cholesteryl ester, free 
cholesterol, triglycerides and apolipoprotein apoB-100 and it is taken up by specific 
LDL receptors on cells (Goldstein et al., 1977). Many of the components of LDL are 
prone to modification, which alters the affinity for the LDL receptor. Modified LDLs are 
taken up nonspecifically by scavenger receptors. In contrast to the LDL-receptor, 
which is downregulated when increased amounts of intracellular cholesterol are 
present, scavenger receptor uptake occurs in a nonspecific and unregulated manner 
and huge amounts of lipids are ingested by macrophages as they keep taking up 
modified LDL (Itabe, 2003). 
The present study involves three different modifications on the LDL particle: oxidation, 
carbamylation and acetylation. Besides oxidation and carbamylation, which are in vivo 
relevant modifications, and therefore explained in detail below, acetylation of LDL has 
not been described as physiological modification of LDL in the human body (Itabe, 
2003). However, acLDL is often used in vitro in macrophage and endothelial cell 
models to initiate stable foam cell formation since it is extensively taken up by cells via 
several scavenger receptors (Goldstein et al., 1979; Kunjathoor et al., 2002). Thus, this 
modification per se has no relevance for atherosclerosis, but it allows the study of 
cholesterol loaded foam cells. 
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2.4.1 Oxidized LDL 
Generally, LDL is protected from oxidation in plasma, but when it is localized in the 
subendothelial space, it is prone to oxidation by both, enzymatic and nonenzymatic 
modifications (Glass et al., 2001). The lipid components as well as the amino acids of 
apoB-100 are susceptible to oxidative modification and the properties of oxidized LDL 
depend on the extent of oxidation. While an early form of oxidized LDL, often referred 
to as minimally oxidized LDL, is still recognized by the LDL-receptor (Navab et al., 
1996), higher oxidized forms of LDL (oxLDL) are taken up by macrophages and 
smooth muscle cells nonspecifically by scavenger receptors (Glass et al., 2001). 
OxLDL contains a fragmented apoB particle, in which lysine residues are covalently 
modified with reactive breakdown products of oxidized lipids (Glass et al., 2001). Thus, 
the LDL-receptor is not able to recognize oxLDL and its nonspecific uptake via 
scavenger receptors on macrophages leads to foam cell formation (Steinberg et al., 
2010). Many scavenger receptors, which mediate the uptake of oxLDL have been 
described. Among them are CD36, LOX-1 (lectin-type oxidized LDL receptor 1) or 
SR-A (scavenger receptor A). SR-BI may also be a ligand for oxLDL (Goyal et al., 
2012). In addition, interaction of oxLDL with macrophages leads to many 
proinflammatory and proatherogenic effects such as induction of cellular and humoral 
immune responses, increased apoptosis and necrosis, increased monocyte adhesion 
to endothelial cells and production of chemokines. These effects may be induced by 
oxLDL binding to scavenger receptors and activation of signal transduction cascades 
(Moore et al., 2006; Miller et al., 2009). 
2.4.2 Carbamylated LDL 
Carbamylation is a posttranslational modification of proteins without involvement of 
enzymes (Jaisson et al., 2011). Structure and functionality of proteins is altered when 
they are carbamylated due to an irreversible reaction of isocyanic acid with amino 
groups and N-terminal groups of amino acids in apoB-100, the main protein 
component of LDL, as schematized in figure 2 (Apostolov et al., 2012). 
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Figure 2: LDL carbamylation 
Figure adapted from Apostolov et al., 2012 
 
Two forms of isocyanic acid formation have been described (figure 2). First, urea 
spontaneously decomposes into cyanate and ammonia, thereafter cyanate is 
immediately converted into isocyanic acid (Jaisson et al., 2011). Another mechanism 
for isocyanic acid formation occurs via the metabolism of thiocyanate, which is an 
abundant anion in blood. Here, cyanate originates from an myleoperoxidase-catalyzed 
oxidation of thiocyanate under consumption of hydrogen peroxide (Wang et al., 
2007b). Isocyanic acid is highly reactive with amino groups of proteins and therefore 
responsible for their carbamylation (Jaisson et al., 2011).  
Carbamylated LDL (cLDL) has several pro-atherogenic effects such as contribution to 
foam cell formation, induction of endothelial cell apoptosis and smooth muscle cell 
proliferation (Ok et al., 2005; Wang et al., 2007b). As compared to native LDL (nLDL), 
the uptake of cLDL via the LDL-receptor is diminished. As a consequence, cLDL is 
cleared from the circulation slower than nLDL in vivo (Hörkkö et al., 1994) and thus 
may undergo additional modification via oxidation. Furthermore, cLDL is recognized by 
macrophage scavenger receptors, presumably SR-A1 (Wang et al., 2007b), and this in 
turn leads to nonspecific uptake of cLDL and induction of unspecific signaling 
pathways. Patients with chronic renal failure have an increased risk for atherosclerosis 
which may, besides other factors, be due to increased plasma urea levels, resulting in 
enhanced carbamylation of (lipo)proteins (Apostolov et al., 2010). 
It is unclear, however, whether macrophages compensate for the increased 
nonspecific uptake of cLDL or whether cellular cholesterol efflux is even unpaired in 
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uremia (Zuo et al., 2009). Thus the present study tries to answer this question by 
investigating cLDL-induced changes in macrophage cholesterol efflux and in the 
expression of the transporters mediating this efflux process. 
2.5 MicroRNAs and atherosclerosis 
MicroRNAs (miRNAs, miRs) are highly conserved, noncoding, single stranded RNA 
molecules with a length of ~22 nucleotides in their mature form (Ambros, 2004). They 
are transcribed from intronic or exonic regions of protein coding genes or intergenic 
regions and after multiple processing steps, mature miRNAs exert their actions post-
transcriptionally on the messenger RNAs (mRNAs) of proteins (Moore et al., 2010). 
Therefore, miRNAs bind preferably to the 3' untranslated region (UTR) by imperfect 
base paring and this causes translational repression or degradation of the target 
mRNA (Chekulaeva et al., 2009). 
Although the contribution of miRNAs to several diseases, such as cancer, has been 
studied intensively (Ha, 2011b; Ha, 2011a), their role in the pathogenesis of 
atherosclerosis is not well defined and studies thereof are rare. MiRNAs have also 
been shown to have an impact on cholesterol homeostasis, and therefore may play a 
role in the development of atherosclerosis (Moore et al., 2010). 
Recent studies showed, that miR-33a downregulates the expression of ABCA1 and 
ABCG1, and hence, plays a role in the regulation of cholesterol efflux. Furthermore, it 
has been reported that intronic regions of the gene encoding SREBP2 include the 
locus of miR-33a and thus, both possibly play in concert in the regulation of the 
cholesterol homeostasis (Rayner et al., 2010). Another regulator of cholesterol 
homeostasis may be miR-223 which targets the mRNA of SR-BI. Moreover, miR-223 is 
significantly increased in mouse models of atherosclerosis as well as in patients with 
familial hypercholesterolemia (Vickers et al., 2011). 
Based on this information, we investigated the influence of modified LDLs on miR-33a 
and miR-223 expression in macrophages to determine a potential role of these 
miRNAs in the regulation of ABCA1, ABCG1 and SR-BI. 
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2.6 Chronic renal failure and atherosclerosis 
Accelerated atherosclerosis is often found in patients with chronic renal failure (CRF). 
The increased risk for atherosclerosis in these patients is thought to be triggered 
primarily by oxidative stress, inflammation and dyslipidemia (Vaziri et al., 2011). CRF 
leads to reduced serum apoA-I and HDL cholesterol concentrations and to impaired 
HDL maturation (Vaziri et al., 2011). Reduced HDL cholesterol and impaired HDL 
maturation is associated with LCAT deficiency as result of renal insufficiency (Moradi 
et al., 2009b). In addition, the composition of HDL in patients with CRF is altered and 
its antioxidant activity is reduced (Moradi et al., 2009a). Increased oxidative stress in 
CRF leads to oxidation of molecules such as LDL (Himmelfarb et al., 2002) which in 
turn are taken up by macrophages of the arterial wall, and as consequence, foam cell 
formation is initiated. Since HDL composition in CRF-patients is altered, its reverse 
cholesterol transport capacity may be reduced (Vaziri et al., 2011).  
Moreover, elevated plasma urea levels in patients with CRF induce the LDL 
carbamylation (Jaisson et al., 2011) which is known to be an atherogenic factor 
(Apostolov et al., 2010) as described in cpt. 2.4.2. Besides LDL, also HDL may 
undergo carbamylation. However, the carbamylation of HDL has not been studied as 
intensively as that of LDL. Carbamylated HDL (cHDL) has been reported to contribute 
to foam cell formation in tissue culture and it was found in atherosclerotic lesions in 
high concentrations (Holzer et al., 2011). We studied the cholesterol efflux capacity of 
cHDL and of serum from patients with either CRF or end stage renal disease (ESRD) 
on hemodialysis treatment. 
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3 Aim 
Foam cells are the main component of the fatty streak and they are characteristic for 
early atherosclerotic lesions. Due to the extensive uptake of modified lipoproteins, 
foam cells contain massive amounts of cholesteryl esters (Libby et al., 2011). 
Carbamylation of LDL is increased in patients with CRF as result of uremia. The 
uptake of cLDL by macrophages induces foam cell formation and therefore is 
considered as atherogeneic (Jaisson et al., 2011). 
So far, most studies have investigated the effects of cLDL in endothelial cells but little 
is known about its effect on (human) macrophages. Therefore, our first aim was to 
determine whether cLDL alters the expression of the efflux transporters ABCA1 and 
ABCG1 on a protein and mRNA level in THP-1 macrophages as response to 
excessive cholesterol uptake. The bidirectional receptor SR-BI may also play a role in 
the efflux of cholesterol (Valacchi et al., 2011). Therefore, we also examined the effect 
of cLDL on SR-BI protein and mRNA expression. Moreover, cholesterol efflux from 
THP-1 macrophages incubated with cLDL and nLDL to apoA-I, HDL and serum was 
measured to find any possible alterations. Since the transcription factor LXRα 
regulates ABCA1 and ABCG1 expression (Tall, 2008), it was of interest whether cLDL 
induces a change in LXRα mRNA expression, and in addition, it was tested whether 
antagonizing LXR reverses any possible effect. 
Another aim was to characterize the mRNA and protein expression of ABCA1, ABCG1, 
SR-BI and LXRα during THP-1 differentiation from the monocytic state to 
macrophages. The gene expression of ABCA1, ABCG1 (reviewed by Tall, 2008) and 
SR-BI (Malerod et al., 2002; Hu et al., 2010) is regulated by LXRα in differentiated 
macrophages. We asked, whether the expression of this set of genes correlates with 
that of LXRα during THP-1 differentiation as well. 
Furthermore, we aimed to investigate whether the expression of two specific miRNAs, 
namely miR-33a and miR-223, is altered when THP-1 macrophages are treated with 
different forms of modified LDLs. Both miRNAs are supposed to play a role in 
cholesterol homeostasis: miR-33a inhibits the expression of ABCA1 (Rayner et al., 
2010) and miR-223 may target SR-BI for its degradation or repression (Vickers et al., 
2011). 
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Finally, we studied the cholesterol acceptor capacity of carbamylated HDL to 
determine whether this modification impairs the acceptor capacity of HDL. Like LDL 
and other proteins, HDL is subject to carbamylation under uremic conditions (Wang et 
al., 2007b). In this context, we also measured the cholesterol acceptor capacity of 
serum obtained from patients with CRF or ESRD on hemodialysis treatment. 
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4 Materials and Methods 
Chemicals used throughout the experiments were purchased from Merck (E.Merck, 
Darmstadt, Germany); Roth (Carl Roth GmbH, Karlsruhe, Germany) or Sigma (Sigma-
Aldrich, St. Louis, USA) unless noted otherwise. 
4.1 Cell culture 
Two different cell models were used: The human monocytic cell line THP-1 (ATCC 
TIB-202) was used in most experiments. Primary human monocyte derived 
macrophages (HMDM), were used as a second cell model to confirm several results 
obtained with THP-1 cells. 
4.1.1 THP-1 cells 
THP-1 is a leukemia cell line which was derived from the peripheral blood of a one 
year old infant with acute moncytic leukemia (Tsuchiya et al., 1980). Incubation of 
these cells with phorbol esters induces their differentiation into macrophages (Tsuchiya 
et al., 1982). 
Monocytic THP-1 cells were cultured in cell culture flasks (Greiner Bio One, 
Kremsmünster, Austria) at 37 °C under 5 % CO2 atmosphere in RPMI-1640 medium 
(Rosswell Park Memorial Institute) supplemented with 2 mM L-glutamine, 0.1 mg/ml 
streptomycin, 100 U/ml penicillin (PAA, Pasching, Austria) and 10 % fetal calf serum 
(heat inactivated FCS, Gibco, Life Technologies Corporation, Carlsbad, USA). Cell 
number and viability were measured using a CASY® Cell Counter + Analyser System 
Model TT (Schärfe Systeme, Reuttlingen, Germany) and every two to three days, the 
cells were fed with fresh medium to a density of 0.7*106 cells/ml. 
To differentiate THP-1 cells from monocytes (suspension cells) towards adherent 
macrophages, 0.5*106 cells/ml were incubated with 160 nM PMA (phorbol 12-myristate 
13-acetate) for 72 hours. Therefore, the cells were seeded in multiwell plates (Greiner 
Bio One, Kremsmünster, Austria), provided that the viability was greater than 95 %, as 
measured with the CASY system. Seeding of cells occurred under the conditions as 
described in table 1: 
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Well format Growth area per well (cm²) 
Volume per well 
(ml) 
6 well plate 9.6 3 
12 well plate 3.9 1.2 
24 well plate 1.9 0.6 
Table 1: Seeding of THP-1 cells in multiwell plates 
 
4.1.2 Human monocyte derived macrophages 
For isolation of peripheral blood mononuclear cells (PBMC), venous blood of adult 
fasting healthy volunteers was collected using a Vacuette® blood collection set, 
Vacuette® EDTA (EDTA, ethylene diamine tetra-acetic acid) tubes and Vacuette® 
serum tubes (Greiner Bio One, Kremsmünster, Austria). Isolation of mononuclear cells 
was performed using Ficoll-PaqueTM PREMIUM (GE Healthcare, Buckinghamshire, 
UK), according to the manufacturer's instructions. The entire procedure was carried out 
under sterile conditions. 
EDTA-tubes were centrifuged at 620 x g for 10 minutes at 18 °C without brake. Plasma 
was removed carefully, leaving the lymphocyte interphase intact and replaced by an 
identical volume of RPMI-1640. Blood and RPMI-1640 were gently mixed. Plasma was 
stored at 4 °C for lipoprotein preparation (see next section). Serum tubes were 
centrifuged at 1500 x g for 10 minutes at 18 °C and the upper serum layer was 
transferred to a new tube. An aliquot of serum was removed and stored at 4 °C until 
use on the same day. From the remaining serum, aliquots were prepared and stored at 
-20 °C. 
Next, a tube containing Ficoll-PaqueTM PREMIUM was prepared and an equal volume 
of the blood/RPMI-sample was layered over the Ficoll-Paque solution without allowing 
both phases to mix. Then, the samples were centrifuged at 320 x g for 30 minutes at 
18 °C without brake. After centrifugation, four distinct layers were distinguishable. The 
uppermost layer contained medium, remaining plasma and platelets. The second layer 
was a white ring of PBMC. Beneath this ring, a layer containing Ficoll-Paque solution 
was present and the bottom layer was composed of erythrocytes and granulocytes. 
The uppermost layer was drawn off and the PBMC ring was collected into a tube with 
fresh media for washing. Therefore, the cell isolate was suspended gently in 30 ml 
media and afterwards centrifuged at 320 x g for 10 minutes at 18 °C. Subsequently, 
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the supernatant was removed and the cell pellet was resuspended in fresh media for 
another wash and centrifugation cycle. The resulting pellet was finally resuspended in 
RPMI-1640 medium supplemented with 2 mM L-glutamine, 0.1 mg/ml streptomycin, 
100 U/ml penicillin and 10 % autologous serum. The cells were then seeded (for 
volume see table 2) onto cell culture multiwell plates and incubated at 37 °C under 5 % 
CO2 atmosphere. Autologous serum initiates the differentiation of monocytes towards 
macrophages. The cells were allowed to adhere to the cell culture plate for two hours. 
During differentiation, the morphology changes from spherical suspension cells to 
elongated adherent cells. After these two hours, the medium was replaced with a 
smaller volume of fresh medium (same supplements, for volume see table 2). The next 
media change was carried out after two days. Until complete differentiation towards 
macrophages, which was achieved after one week, cells were fed every two days with 
supplemented medium. After this week, HMDM were ready for use in experiments. 
 
Well format Growth area per 
well (cm²) 
Seeding 
volume per 
well (ml) 
Feeding 
volume per 
well (ml) 
6 well plate 9.6 4 2 
12 well 
plate 
3.9 2 0.75 
24 well 
plate 
1.9 1 0.35 
Table 2: Seeding and feeding of HMDM in multiwell plates 
 
In general, one EDTA-tube containing 9 ml of full blood was used to seed one well of a 
6 well plate or two wells of a 24 well plate. 
4.2 Lipoprotein preparation 
The lipoproteins used throughout the experiments were isolated from venous blood of 
healthy, adult fasting volunteers via sequential ultracentrifugation. 
4.2.1 Isolation of lipoproteins 
Blood was collected in tubes containing EDTA (0.18 M EDTA, pH 8; 2 ml per 50 ml 
blood) to inhibit the blood coagulation cascade. Then, the EDTA-blood samples were 
centrifuged at 620 x g for 10 minutes at room temperature without brake. Next, the 
upper phase, which represents the plasma, was collected and lipoproteins were 
separated according to Schumaker et al., 1986. In brief, the density of the plasma was 
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first adjusted to the density of VLDL (i.e. 1.019 g/cm³) with potassium bromide (KBr). 
For calculation of the required amount of KBr in gram, the following formula was used: 
Volumesample (ml) x (Densityfinal – Densityinitial) 
g KBr = 
1 – (0.312 x Densityfinal) 
Afterwards, the plasma was filled in centrifuge tubes (Quick-SealTM centrifuge tubes, 
Beckman Instruments Inc, Palo Alto, USA) and centrifuged at 51,000 rpm (200,000 x 
g) in an ultracentrifuge (OptimaTM L-100 XP Ultracentrifuge, rotor type: 55.2 Ti, 
Beckman Coulter, Brea, USA) for 20 hours at 4 °C. Then, VLDL, which was contained 
in the top fraction, was collected with a syringe after slicing the top of the tube. 
Afterwards, the remaining plasma fraction (i.e. without VLDL) was adjusted to the 
density of LDL (1.063 g/cm³) with KBr and centrifuged (same conditions as for VLDL). 
Following centrifugation, LDL was collected from the top phase of the centrifuge tube 
and the remaining plasma was adjusted to the density of HDL (1.22 g/cm³). A further 
centrifugation step was performed in order to collect HDL in the top fraction of the tube. 
Finally, the collected HDL fraction was centrifuged again for further purification and to 
ensure complete removal of other constituents such as albumin. LDL and HDL were 
dialyzed against dialysis buffer (154 mM NaCl, 3 mM EDTA, pH 7.4) for 24 hours at 
4 °C to remove KBr from the fractions. 
4.2.2 Low-Density-Lipoprotein (LDL) modification 
In vitro modification of LDL was performed to obtain carbamylated LDL (cLDL), 
oxidized LDL (oxLDL) or acetylated LDL (acLDL) as follows: 
Carbamylation of LDL was performed via incubation of 2 mg/ml LDL in 50 mM 
phosphate buffer containing 246.5 mM, 123.25 mM or 61.5 mM KCNO in a reaction 
volume of at least 100 µl for 4 hours at 37 °C. To remove KCNO from the solution, 
cLDL was purified via gel exclusion chromatography (illustraTM NICKTM column, GE 
Healthcare, Buckinghamshire, UK). Therefore, 100 µl cLDL were eluted with 400 µl 
PBS (phosphate buffered saline, 137 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8.1 mM 
Na2HPO4, pH 7.4). LDL carbamylated with 246.5 mM KCNO was used for incubation 
of cells, whereas less carbamylated LDL samples were exclusively used for the 
analysis of their relative electrophoretic mobility (cpt 4.2.4). 
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For oxLDL, 2 mg/ml LDL was passed over a NICKTM column to remove EDTA, which is 
contained in the ultracentrifuged and dialyzed LDL fraction, by chromatography 
(illustraTM NICKTM column, same procedure as for cLDL) and then incubated with 
10 µM CuSO4 for 4 hours at 37 °C. Then, CuSO4 was inactivated by adding 50 µM 
EDTA in order to chelate copper. 
Acetylation of LDL was accomplished by adding LDL (2 mg/ml) to the same volume of 
saturated sodium-acetate. The mixture was gently stirred on ice and five times, every 
10 minutes, acetic acid anhydride (0.01 % (v/v) of the final volume) was added. Then, 
the solution was gently stirred on ice for additional 30 minutes and afterwards dialyzed 
against dialysis buffer for 24 hours at 4 °C. 
Unmodified LDL (native LDL, nLDL), used as a control, was also run through a NICKTM 
column for removal of EDTA. All LDL solutions were sterile filtered through a sterile 
0.45 µm filter (Arcodisk®, Gelman Sciences, Michigan, USA). 
4.2.3 High-Density-Lipoprotein (HDL) modification 
HDL was carbamylated in vitro using the same method as described for LDL. 
Therefore, 2 mg/ml HDL were incubated with 50 mM phosphate buffer containing 
varying concentrations of KCNO for 4 hours at 37 °C. To obtain HDL samples with 
different degrees of carbamylation, the KCNO concentrations were 246.5 mM, 
123.3 mM, 61.6 mM, 30.8 mM 15.4 mM, 7.7 mM and 3.9 mM. After 4 hours of 
incubation, the cHDL samples were purified from KCNO via gel exclusion 
chromatography (NICKTM column). 100 µl cHDL were eluted with 400 µl PBS. 
Unmodified HDL (native HDL, nHDL) was also run through a NICKTM column for 
removal of EDTA. 
To confirm the results obtained with individual carbamylated HDL samples, another 
method was used to prepare HDL samples with different amounts of carbamylated 
particles. Therefore, one HDL sample was carbamylated with 246.5 mM KCNO as 
described above. The cHDL sample was further diluted stepwise 1:1 with nHDL to 
yield nine less carbamylated samples. 
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4.2.4 Analysis of the relative electrophoretic mobility of carbamylated 
lipoproteins by agarose gel electrophoresis 
Carbamylation changes the electrophoretic properties of proteins. The modification of 
lysine amino groups of proteins leads to the removal of positive charge from the 
protein and therefore, the electrophoretic mobility of carbamylated proteins differs from 
their native forms (for review see Jaisson et al., 2011). 
Native and carbamylated samples of LDL and HDL were loaded onto a 1 % agarose 
gel. For agarose gel preparation, 1 % agarose was dissolved in TAE buffer (Tris-
Acetate-EDTA; 40 mM Tris, 20 mM acetic acid, 1 mM EDTA, pH 8.0) and boiled in a 
microwave. The gel was poured into a gel-tray and a 8-well comb was inserted. After 
assembly, the electrophoresis chamber was filled with TAE buffer. The comb was 
removed from the gel and samples (each containing 10 µg protein) with loading dye 
(6x DNA loading dye; Fermentas GmbH, St. Leon-Rot, Germany) were loaded into the 
slots. Electrophoresis was performed at 90 Volts for 90 minutes. Subsequently, the gel 
was stained with Coomassie staining solution composed of 0.1 % Coomassie blue, 
30 % methanol and 10 % acetic acid for 15 minutes. Afterwards, the gel was destained 
in 20 % methanol, 10 % acetic acid, 70 % ddH2O overnight. Finally, the gel was 
photographed for further analysis of the relative electrophoretic mobility (REM). 
4.2.5 Assessment of carbamylation 
The degree of carbamylation in lipoprotein preparations was measured using a 
colorimetric method (Trepanier et al., 1996). Therefore, 20 µg of lipoprotein were 
digested in a volume of 50 µl containing PBS (pH 7.4), 2 µg proteinase K and 1 % 
sodium dodecyl sulfate (SDS) at 37 °C for 2 hours. Afterwards, 250 µl of urea-nitrogen-
reagent (0.83 M sulfuric acid, 1.13 M orthophosphoric acid, 0.55 mM 
thiosemicarbazide, and 2.6mM cadmium sulfate) and 50 µl diacetyl monoxime (3 % in 
ddH2O) were added and incubation continued at 97 °C for 30 minutes. To remove 
precipitates, the samples were centrifuged at 3500 x g for 10 minutes at room 
temperature. The supernatant was transferred to a new tube and centrifuged again for 
complete removal of precipitates. Then, 200 µl of the supernatant was transferred into 
a 96-well plate and absorption was measured at 535 nm. A standard curve was 
created using 0, 1.875, 3.73, 7.5, 15 and 30 nmol ε-amino-carbamyllysine (L-
homocitrulline (Hcit), Chemos GmbH, Regenstauf, Germany) in the particular 
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standard. Standards underwent the same treatment as samples. The measurements of 
the samples were interpolated from the standard curve and expressed in µmol Hcit/g 
protein. 
4.3 Protein determination 
For determination of protein the Bio-Rad Protein Assay (Bio-Rad Laboratories GmbH, 
Munich, Germany) was used. The assay is based on the observation that binding of an 
acidic solution of Coomassie Brilliant Blue G-250 to protein shifts the absorbance 
maximum from 465 nm to 595 nm (Bradford, 1976). 
For this purpose, 1-10 µl of a sample with unknown protein concentration was added to 
20 µl Bio-Rad Protein Assay reagent placed in a 96-well plate and filled up with 
distilled water to a total volume of 100 µl. To create a standard curve consisting of 
known protein concentrations, bovine serum albumin (BSA) was used. Absorbance at 
595 nm was measured in a microplate reader (Bio-Rad, iMarkTM microplate reader) 
after 5 to 30 minutes. The concentrations of the unknown protein samples were 
interpolated from the standard curve. 
4.4 RNA isolation from THP-1 cells 
RNA was isolated from THP-1 cells using the RNeasy® Plus Micro Kit (Qiagen, Hilden, 
Germany). Therefore, the cells were washed twice with PBS and then exposed to 
350 µl RLT Plus buffer including 1% β-mercaptoethanol for disruption. Then, the lysate 
was passed several times through a 20-gauge needle (0.9 mm diameter) fitted to a 
syringe for homogenization. To obtain an efficient cell lysis, the lysates were frozen at 
-80 °C until further processing. After thawing, the isolation procedure was performed 
as described by the manufacturer. Finally, RNA was eluted with 15 µl RNase free 
water and the concentration of each sample was determined spectrophotometrically 
(NanoDrop® ND-1000, NanoDrop Technologies, Wilmington, USA). RNA was stored at 
-80 °C until further use. From cells seeded in a well of a 12 well plate (3.9 cm² growth 
area per well), 120 to 3600 ng RNA were recovered (dependent on cell confluency). 
4.5 MicroRNA isolation from THP-1 cells 
The isolation of miRNA from THP-1 cells was performed using the miRNeasy® Mini Kit 
(Qiagen, Hilden, Germany). For this purpose, cells were washed twice with PBS before 
lysis with QIAzol Lysis Reagent. The lysate was homogenized by passing it several 
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times through a 20-gauge needle (0.9 mm diameter) fitted to a syringe. Further 
processing for miRNA isolation was performed as described by the manufacturer. 
Finally, miRNA was eluted with 75 µl RNase free water, the concentration was 
determined spectrophotometrically and stored at -80 °C until further use. From the 
cells seeded in one well of a 6 well plate (9.6 cm² growth area per well), 120 to 
3600 ng miRNA were recovered (dependent on cell confluency). 
4.6 Reverse Transcription PCR 
All reagents and materials used in reverse transcription PCR and quantitative real-time 
PCR were obtained from Applied Biosystems (Foster City, USA) unless noted 
otherwise. 
4.6.1 Reverse transcription of RNA to cDNA 
To convert RNA into cDNA, RNA was reverse transcribed using the High Capacity 
cDNA Reverse Transcription Kit according to the supplier's protocol. Briefly, a 2X 
master mix including 10X Reverse Transcription (RT) Buffer, 25X dNTP Mix (100 mM), 
10X RT Random Primers, MultiScribeTM Reverse Transcriptase (50 U/µl), RNase 
Inhibitor (20 U/µl) and nuclease-free water was prepared on ice with a total volume of 
10 µl per reaction as follows (table 3): 
 
Reagent µl 
10X RT Buffer 
25X dNTP Mix 
10X RT Random Primers 
Reverse Transcriptase 
RNase Inhibitor 
Nuclease-free Water 
2.0 
0.8 
2.0 
1.0 
1.0 
3.2 
Total volume 10.0 
Table 3: RNA reverse transcription master mix 
 
To prepare the cDNA reverse transcription reaction, 140 ng RNA in 10 µl was added to 
10 µl 2X master mix. The samples were placed into a thermocycler programmed for 
the conditions as instructed in the supplier's protocol (see table 4). cDNA was stored at 
-20 °C until analyzed by quantitative real-time PCR. 
 
 Step 1 Step 2 Step 3 Step 4 
Temperature (° C) 25 37 85 4 
Time 10 min 120 min 5 min ∞ 
Table 4: Thermal cycler conditions for reverse transcription of RNA 
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4.6.2 Reverse transcription of miRNA to cDNA 
TaqMan® MicroRNA Reverse Transcription Kit was used for reverse transcription of 
miRNA to cDNA as outlined in the supplier's manual. In brief, a master mix composed 
of 100 mM dNTPs, MultiscribeTM Reverse Transcriptase (50 U/µl), 10X Reverse 
Transcription Buffer, RNase Inhibitor (20 U/µl) and nuclease-free water was prepared 
on ice as described in table 5. 
 
Reagent µl 
100 mM dNTPs 
Reverse Transcriptase 
10X RT Buffer 
RNase Inhibitor 
Nuclease-free Water 
0.15 
1.00 
1.50 
0.19 
1.16 
Master mix - total volume 4.00 
Table 5: miRNA reverse transcription master mix 
 
3 µl of the corresponding 5X TaqMan® MicroRNA Assay (see table 6) was added to 
the master mix. Additionally, 3 µl of 5X RT Primer miR-16 or RNU44 was added to 
each reverse transcription assay as endogenous controls during real-time PCR. 
 
5X TaqMan® MicroRNA Assay 
(Applied Biosystems) 
ID 
hsa-miR-16 
RNU44 
hsa-miR-223 
hsa-miR-33a 
RT:000391 
RT:001094 
RT:002295 
RT:002135 
Table 6: Primers used for miRNA conversion 
(the prefix "hsa" stands for "homo sapiens" for species designation) 
 
To this 10 µl reaction mix, 100 ng miRNA in 5 µl was added for preparation of the 
cDNA reverse transcription. The samples were incubated on ice for 5 minutes and 
afterwards placed into a thermal cycler programmed for the conditions as described in 
the supplier's protocol (see table 7). Until performing quantitative real-time PCR, the 
cDNA samples were stored at -20 °C. 
 
 Step 1 Step 2 Step 3 Step 4 
Temperature (° C) 16 42 85 4 
Time 30 min 30 min 5 min ∞ 
Table 7: Thermal cycler conditions for reverse transcription of miRNA 
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4.7 Measurement of mRNA expression by quantitative real-time 
PCR 
Quantitative real-time PCR (qPCR) experiments were performed to investigate the 
effect of different concentrations of cLDL and nLDL on ABCA1, ABCG1, SR-BI 
(SCARB1) and LXRα (NR1H3) mRNA expression. Additionally, ABCA1, ABCG1, 
SR-BI and LXRα mRNA levels were quantified during different time points of THP-1 
differentiation via qPCR. 
For quantitative real-time PCR, 2 µl reverse transcribed RNA (14 ng) were added to 
7.5 µl TaqMan® Gene Expression Master Mix, 0.756 µl of the corresponding TaqMan® 
Gene Expression Assay (table 8) and 4.75 µl nuclease-free water resulting in a final 
volume per reaction of 15 µl. 
 
TaqMan® Gene Expression Assay 
(Applied Biosystems) 
ID 
ABCA1 
ABCG1 
SCARB1 
NR1H3 
18S 
Hs00194045_m1 
Hs01555193_m1 
Hs00969821_m1 
Hs00172885_m1 
Hs99999901_s1 
Table 8: Description of primers used for qPCR (mRNA) 
 
Samples were measured in duplicates in a 48-well reaction plate (MicroAmpTM Fast 
Optical 48-Well Reaction Plate) sealed with adhesive film (MicroAmpTM 48-Well Optical 
Adhesive Film). Negative control samples contained nuclease-free water instead of 
cDNA. TaqMan® Gene Expression Assays for reverse transcribed 18S rRNA were 
used as endogenous control and cDNA from cells treated with BSA were used as 
reference sample. After sealing with adhesive film, the plate was centrifuged for 1 
minute at 1800 x g to eliminate any air bubbles and for spinning down the contents. 
Then, the plate was placed in a real-time PCR system (StepOneTM Real-Time PCR 
System) to start the PCR reactions according to the thermal cycling program (see table 
9) of the supplier's protocol. Before starting the real-time PCR system, the setup of the 
plate was defined via the StepOneTM Software (Version 2.1). The experiment type was 
set to "Quantitation – Comparative CT (∆∆CT)", as the expression of 18S rRNA was 
used as endogenous control for relative quantitation (RQ) of the respective target 
(ABCA1, ABCG1, SR-BI or LXRα mRNA) contained in the sample relative to the 
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reference sample (BSA incubation). After completion of the run, the CT values were 
used for relative quantitation. 
 
UDG 
incubation 
Polymerase 
activation PCR 
Cycle (40 cycles) 
 
Hold Hold Denature Anneal/extend 
Temperature (° C) 50 95 95 60 
Time 2 min 10 min 15 sec 1 min 
Table 9: Thermal cycler conditions for quantitative real-time PCR (mRNA) 
 
UDG (uracil-DNA glycosylase), contained in the TaqMan® Gene Expression Master 
Mix, prevents reamplification of carryover-PCR products (from the reverse transcription 
reaction) during the assay as outlined in the manufacturer's manual.  
4.8 Measurement of miRNA expression by quantitative real-time 
PCR 
For analyzing the effect of cLDL, oxLDL, acLDL and nLDL on miRNA gene expression 
of miR-223 and miR-33a in THP-1 cells, quantitative real-time PCR was performed. 
For this purpose, 1.33 µl of reverse transcribed miRNA (i.e. 8.9 ng) were incubated 
with 10 µl TaqMan® Universal Master Mix II (without UDG), 7.67 µl nuclease-free 
water and 1 µl of the corresponding 20X TaqMan® MicroRNA Assay (table 10) to give 
a total volume of 20 µl per reaction. 
 
20X TaqMan® MicroRNA Assay 
(Applied Biosystems) 
ID 
hsa-miR-16 
RNU44 
hsa-miR-223 
hsa-miR-33a 
TM:000391 
TM:001094 
TM:002295 
TM:002135 
Table 10: Primers used for qPCR (miRNA) 
 
The rest of the procedure was similar to qPCR of mRNA (see above). Samples were 
applied in duplicates on a 48-well reaction plate (MicroAmpTM Fast Optical 48-Well 
Reaction Plate) and sealed with adhesive film (MicroAmpTM 48-Well Optical Adhesive 
Film) to avoid evaporation and contamination. Negative control samples contained 
nuclease-free water only instead of cDNA. TaqMan® MicroRNA Assays for miR-16 
and RNU44 were used as endogenous controls and the cDNA of cells incubated with 
BSA was used as reference sample. To spin down the contents and for elimination of 
any air bubbles, the plate was centrifuged for 1 minute at 1800 x g. 
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Before starting the reactions with simultaneous measurement in a real-time PCR 
system (StepOneTM Real-Time PCR System), the plate setup was defined in the 
StepOneTM Software (Version 2.1). The type of experiment was set to "Quantitation – 
Comparative CT (∆∆CT)", as an endogenous control (miR-16 or RNU44) was used for 
relative quantitation of the respective target (miR-223 or miR-33a) in the sample 
relative to the reference sample (BSA incubation). The thermal cycling conditions of 
the real-time PCR system were set according to the instructions of the manufacturer's 
protocol (see table 11). After completion of the run, the CT values were used for 
relative quantitation. 
 
Polymerase 
activation PCR 
Cycle (40 cycles) 
 
Hold Denature Anneal/extend 
Temperature (° C) 95 95 60 
Time 10 min 15 sec 1 min 
Table 11: Thermal cycler conditions for quantitative real-time PCR (miRNA) 
 
4.9 Western Blotting 
4.9.1 Cell lysis 
THP-1 macrophages or HMDM on 6-well plates were placed on ice and washed twice 
with cold (4 °C) PBS. For lysis, cells were incubated with 40-80 µl (depending on cell 
confluency) membrane lysis buffer (62.5 mM Tris pH 6.8, 8 M urea, 20 mM EDTA, 
20 mM EGTA, 10 % glycerol, 1 % SDS) supplemented with protease inhibitor cocktail 
(1:100; Sigma, catalog number: P8340) for 10 minutes. Afterwards, the cells were 
scraped with a rubber policemen for efficient detachment from the bottom of the well. 
Then, the lysates were transferred to an Eppendorf tube, sonicated for 5 seconds, 
incubated on ice for one hour and stored at -20 °C for at least one week to increase 
lysis efficiency. Then, samples were thawed on ice for one hour and then centrifuged 
at 14,000 x g for 10 minutes to remove any precipitates. The supernatant was 
transferred into a new tube and the protein concentration was determined using the 
Bradford Assay (see cpt. 4.3). 
4.9.2 Sample preparation 
Samples were prepared for SDS-PAGE by diluting equal amounts of protein (7 µg 
protein per lane on SDS gel) with PBS. Proteins were denaturated by adding freshly 
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prepared 4X sample buffer (50 % glycerol, 45 % 0.5 M Tris-HCl pH 6.8 with 8 % SDS, 
5 % β-mercaptoethanol, dash of bromphenol blue) with subsequent incubation for 30 
minutes at 40 °C. The samples were allowed to reach room temperature before they 
were loaded onto the gel. 
4.9.3 SDS-PAGE 
The Mini-PROTEAN 3 Cell (Bio-Rad) was used for gel preparation according to the 
manufacturer's handbook. 
For the resolving gel (8%) the first three components listed in table 12 were mixed. As 
APS and TEMED start the polymerization reaction of the gel, both substances were 
added immediately before pouring the gel. Proper mixing of all ingredients was 
assured by vortexing. After casting the resolving gel between a short glass plate and a 
0.75 mm spacer plate, it was overlaid instantly with isopropanol to prevent the gel from 
drying out and to avoid air contact and thereby ensuring complete polymerization. After 
30 minutes, the resolving gel was polymerized, isopropanol was removed and the 
prepared stacking gel solution (4 %, composition described in table 12) was poured 
onto the resolving gel. Finally, a 15-well comb was inserted between the glass plates 
and the gel was allowed to polymerize for another 30 minutes. 
 
 Resolving gel 
(8 %) 
Stacking gel 
(4 %) 
ddH20 1.6 ml 1.1 ml 
30 % acrylamide/N,N’-
methylene-bis-acrylamide 
(29.2:0.8) 
1.1 ml 0.3 ml 
3 M Tris-HCl pH 8.45, 
0.3 % SDS 1.3 ml 0.7 ml 
10 % APS 30 µl 20 µl 
TEMED 3 µl 2 µl 
Table 12: Components of SDS-PAGE gel (for 1 gel 72x100 mm, spacer 
0.75 mm) 
 
After complete polymerization, the gel cassettes were inserted into the electrophoresis 
module. Tris/Glycine buffer (25 mM Tris, 192 mM glycine, 0.1 % SDS, pH 8.3) was 
used as electrophoresis buffer. The comb was removed from the gel and the slots 
were rinsed with electrophoresis buffer. The slots were loaded with the samples (cpt. 
4.9.2) and a protein ladder (SpectraTM Multicolor High Range Protein Ladder, 
Fermentas GmbH) and empty slots were filled with sample buffer. 
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Electrophoresis was carried out at 4 °C for 85 minutes at a constant voltage of 180 
Volts. After completion of the run, the gel cassette was removed from the 
electrophresis module and the gel was detached from the glass plates for transfer. 
4.9.4 Electrophoretic transfer 
The gel was blotted onto a nitrocellulose membrane (0.45 µm, Bio-Rad) using the Mini 
Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad) according to the manufacturer's 
manual. The transfer sandwich unit was assembled as described in the instructions as 
follows: 
 
 
White side of gel holder cassette 
Fiber pad 
Filter paper 
Nitrocellulose membrane 
Gel 
Filter paper 
Fiber pad 
Black side of gel holder cassette 
 
 
Table 13: Assembly of transfer sandwich for Western blot according to the 
supplier's instructions 
 
Prior to assembly, fiber pads, filter paper and the nitrocellulose membrane were wetted 
with Transfer Buffer (Tris/Glycin Buffer, 20 % methanol). Any air bubbles between 
nitrocellulose membrane and gel were rolled out with a glass tube. 
After complete assembly of the transfer sandwich, the gel holder cassette was locked 
and placed in the electrophoresis module together with an ice block to ensure cooling 
during transfer. Then the transfer was performed at 4 °C for 43 minutes with a constant 
electric current of 0.4 ampere. 
Subsequent to the transfer, the nitrocellulose was incubated with Ponceau S staining 
solution (1 % Ponceau S, 30 % trichloroacetic acid, 30 % sulfosalicylic acid) for 5 
minutes to visualize proteins. Thereafter, excess staining solution was removed, the 
nitrocellulose was rinsed with deionized water and was cut according to the molecular 
mass of proteins studied, as indicated by the protein ladder. Afterwards, the 
nitrocellulose membrane strips were washed with Tris-Buffered Saline Tween (TBS-T; 
20 mM Tris, 145 mM NaCl, 0.1 % Tween-20, pH 7.4) for 10 minutes to completely 
remove Ponceau S staining solution. 
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4.9.5 Immunological detection of proteins 
To block nonspecific sites, the nitrocellulose membrane strips were incubated with 
blocking buffer (TBS-T with 5 % nonfat dry milk, Maresi, Vienna, Austria) for 1 hour. 
After blocking, the strips were washed three times (10 minutes each) with TBS-T and 
incubated with the respective primary antibody solution (table 14) overnight at 4 °C. 
 
Antibody 
(species 
reactivity: 
human) 
Host Supplier Product ID 
Position  
of protein 
band 
Dilution 
Anti-ABCA1 
(polyclonal) 
rabbit Novus 
Biologicals 
LCC, 
Littleton, 
USA 
NB400-105 ~ 220 kDa 1:500 in TBS-T 
with 3 % BSA 
Anti-ABCG1 
(polyclonal) 
rabbit Novus 
Biologicals 
LCC 
NB400-132 ~ 76 kDa 1:2000 in TBS-T 
with 3 % BSA 
Anti-SR-BI 
(polyclonal) 
rabbit Novus 
Biologicals 
LCC 
NB400-104 ~ 82 kDa 1:3000 in TBS-T 
with 2.5 % 
nonfat dry milk 
Anti-β actin 
(monoclonal) 
mouse Sigma 
Aldrich 
A2228 ~ 42 kDa 1:3000 in TBS-T 
with 3 % BSA 
Table 14 : Primary antibodies used for Western blot 
 
A dash of sodium azide was added as preservative to all primary antibody solutions. 
The solutions were stored at 4 °C and were reused several times. 
After overnight incubation of the nitrocellulose membranes, the primary antibody 
solutions were removed and the membranes were washed three times (10 minutes 
each) with TBS-T. Next, incubation with secondary antibody was carried out. 
Therefore, all secondary antibody solutions were freshly prepared in blocking buffer. 
For the ABC-transporters (ABCA1 and ABCG1) and SR-BI, Goat Anti-Rabbit IgG-HRP 
Conjugate (Bio-Rad) was diluted 1:8000 or 1:11250, respectively, in blocking buffer. 
For β-actin, Goat Anti-Mouse IgG-HRP Conjugate (Bio-Rad) was diluted 1:15000 in 
blocking buffer. The respective nitrocellulose membrane strips were incubated with 
secondary antibody solutions for 1 hour at room temperature. Another three washes 
with TBS-T followed after exposure to secondary antibody. 
Thereafter, a chemiluminescence working solution (SuperSignal West Dura Extended 
Duration Substrate, Thermo Fisher Scientific Inc., Rockford, USA) was prepared by 
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mixing equal parts of the Stable Peroxide Solution and the Luminol/Enhancer Solution. 
The nitrocellulose membranes were incubated with working solution for 5 minutes and 
afterwards, excess liquid was removed. Finally, the membrane was placed below a 
CCD camera in a dark chamber of an image acquisition system (Fusion FX7; Peqlab 
Biotechnologie GmbH, Erlangen, Germany). For detection, an adequate light 
exposure-time of the instrument was chosen. The resulting images were quantified 
using the software AlphaEaseFCTM (Alpha Innotech Corporation, USA). 
As β-actin was used as loading control, each band of ABCA1, ABCG1 and SR-BI was 
normalized to the respective β-actin band. 
4.10 Cholesterol efflux measurements 
Cholesterol efflux experiments were conducted under different circumstances. First, it 
was investigated whether cLDL-treated macrophages have an altered cholesterol 
efflux compared to nLDL-treated macrophages and second, the cholesterol acceptor 
capacities of carbamylated HDL versus native HDL as well as the cholesterol acceptor 
capacities of serum from CRF and ESDR patients versus serum from healthy controls 
were studied. 
4.10.1 Measurement of the effect of carbamylated LDL on the cholesterol efflux 
capacity of macrophages 
THP-1 macrophages and differentiated HMDM, grown on 24-well plates, were 
incubated with either cLDL or nLDL (both 50 µg/ml) for 48 hours. 24 hours prior to the 
efflux experiment, 0.5 µCi [³H]-cholesterol (PerkinElmer Inc, Waltham, USA) was 
added per well. Then, cholesterol efflux was measured to apoA-I (Meridian Life 
Science® Inc, Memphis, USA), HDL (obtained according to the method of cpt 4.2.1), 
serum (obtained from blood of an healthy adult volunteer) and medium. Therefore, the 
cells were washed twice with PBS, and subsequently, the macrophages were 
equilibrated for 2 hours with 250 µl medium per well. Then, the cells were incubated 
with 250 µl/well RPMI-1640 without supplementation or RPMI-1640 supplemented with 
either apoA-I (10 µg/ml), HDL (10 µg/ml), or serum (1 %) for 6 hours at 37 °C. 
Thereafter, the supernatant from the cells was collected and centrifuged at 4 °C for 10 
minutes at 500 x g to remove any cell components. The cells were washed twice with 
PBS and lysed with 250 µl/well 0.1 M NaOH for 1 hour at room temperature. Both, the 
[³H]-cholesterol contained in the cell lysate and the release of [³H]-cholesterol into the 
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cell supernatant were analyzed by scintillation counting. For this purpose, 150 µl of the 
respective cell lysate or centrifuged supernatant was added to 15 ml scintillation fluid 
(BioFluor PlusTM, PerkinElmer). The samples were measured in a β-counter (Tricarb 
2800 TR Liquid Scintillation Analyzer, PerkinElmer) for determination of disintegrations 
per minute (dpm). From the remaining cell lysate, protein determination using Bradford 
assay (cpt. 4.3) was carried out.  
Cholesterol efflux from the cells to the particular acceptor (apoA-I, HDL, serum) was 
expressed in percent of the total dpm (total = dpm of supernatant + dpm of lysate). 
Further, the efflux to medium only (i.e. nonspecific efflux) was subtracted from the 
efflux to the respective acceptors to obtain specific efflux. 
Furthermore, the same experiment was performed with THP-1 cells after blocking the 
ABCA1-mediated cholesterol efflux by probucol as described by Favari et al., 2004. 
Cells were treated with a 10 µM probucol solution during the 2 hour equilibration 
phase. For the probucol working solution, a stock solution (10 mM probucol) was 
prepared in ethanol, which was stored at -20 °C and reused for further experiments. 
Further dilution of the stock solution was carried out in RPMI-1640 supplemented with 
4 % BSA (to maintain solubility) to obtain a concentration of 200 µM probucol. Finally, 
the solution was further diluted to the working solution with RPMI-1640, yielding a final 
concentration of 10 µM probucol, 0.1 % ethanol and 0.2 % BSA. For control 
incubations, cells were treated with the same solution without probucol. 
4.10.2 Measurement of the cholesterol acceptor capacity of HDL and serum 
Differentiated THP-1 macrophages, cultured on 24-well plates, were incubated with 
50 µg/ml acLDL for cholesterol-loading and 3 µM of T0901317 (synthetic LXR-Agonist 
for upregulation of ABCA1 and ABCG1) and were trace-labeled with 0.5 µCi [³H]-
cholesterol 24 hours prior to the efflux experiment. On the day of the efflux experiment, 
cells were washed with PBS, equilibrated with medium and afterwards incubated with 
10 µg/ml carbamylated HDL for 6 hours. The cHDL samples were carbamylated to 
obtain different degrees of carbamylation (see cpt. 4.2.3). Efflux was measured as 
described above (cpt. 4.10.1). 
A similar experiment was performed with differentiated HMDM. These cells were also 
incubated with acLDL, [³H]-cholesterol and T0901317 (same concentrations as for 
THP-1) the day before the efflux experiment. After washing with PBS and equilibration 
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with medium, the cells were incubated with 10 µg/ml cHDL (carbamylated with 
246.5 mM KCNO), 10 µg/ml nHDL or medium for 6 hours to measure efflux. 
Another field of interest was to determine the efflux capacity of serum of patients (cpt. 
4.11) with CRF or ESRD on hemodialysis treatment compared to the efflux capacity of 
serum of healthy controls. Therefore, THP-1 macrophages and HMDM were treated 
with 50 µg/ml acLDL, 0.5 µCi [³H]-cholesterol and 3 µM T0901317 for 24 hours. Cells 
were washed with PBS and equilibrated with medium for 2 hours prior to incubation 
with medium supplemented with 1 % serum of patients or respective healthy controls 
for 6 hours. Afterwards, efflux was measured as described above. Efflux of HMDM was 
measured to pooled serum of the respective groups in 4 independent experiments. 
4.11 Patients 
For this study 17 adult patients suffering from CRF KDOQI (National Kidney 
Foundation Kidney Disease Outcomes Quality Initiative) stage 3-5 without 
hemodialysis and 14 adult CRF patients on maintenance hemodialysis and matched 
controls were recruited (see table 15 for details). The study was approved by the 
Ethics Committee of the Medical University of Vienna (Protocol # 511/2007). Written 
informed consent was obtained from all participants. Patients with diabetes mellitus, 
nephrotic syndrome, inflammatory diseases, malignancy and infections within the last 
3 months, and patients on corticosteroids, lipid lowering or immunosuppressive drugs 
were excluded. 20-30 ml of venous blood was collected after an overnight fast. EDTA 
plasma was stored at 4 °C for lipoprotein isolation and serum was frozen in aliquots at 
-20 °C for lipid and apolipoprotein analysis. Monocytes were isolated from EDTA blood 
and differentiated towards macrophages. 
4.12 Statistical Analysis 
Data analysis was performed using the statistical software package GraphPad Prism® 
Version 5.00 (GraphPad Software Inc., La Jolla, USA). Data are expressed as means 
± standard deviation (SD) and analyzed via unpaired t-test, one-way analysis of 
variance (ANOVA) with Newman-Keuls post test or two-way ANOVA with Bonferroni 
post test. Differences were considered statistically significant if p < 0.05. 
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5 Results 
5.1 Characterization of carbamylated lipoproteins 
In vitro carbamylated lipoproteins were analyzed regarding their change in 
electrophyoretic mobility as well as their degree of carbamylation via a colorimetric 
assay as quality control experiments. 
5.1.1 Relative electrophoretic mobility of carbamylated and native lipoproteins  
As carbamylation increases the overall negative charge of a protein, carbamylated 
proteins have different eletrophoretic mobilities compared to uncarbamylated proteins. 
Thus, carbamylated proteins move faster towards the positive pole during agarose gel 
electrophoresis (Kraus et al., 2001). 
To investigate the change in electrophoretic mobility, agarose gel electrophoresis of 
liporoteins, carbamylated with different concentrations of potassium cyanate, was 
performed. In this assay, the electrophoretic mobilities of the native forms of LDL and 
HDL (lane 1 and lane 5, respectively, see figure 3) were set to 1.  
 
 
Figure 3: Relative electrophoretic mobility of 
carbamylated lipoproteins 
Cathode is at the top of the figure. 
Lipoproteins were applied as follows: 
nLDL (lane 1), 
LDL carbamylated with 246.5 mM (lane 2), 
123.25 mM (lane 3), 61.6 mM (lane 4) KCNO 
nHDL (lane 5), 
HDL carbamylated with 246.5 mM (lane 6), 
123.25 mM (lane 7), 61.6 mM (lane 8) KCNO 
For both, LDL and HDL, REM increased with increasing KCNO concentration used for 
carbamylation. Concerning LDL, the REM (indicated in figure 3) of the highest 
carbamylated sample doubled in comparison to its native form and decreased when 
carbamylation decreased. A similar pattern could be recognized for HDL, the highest 
KCNO concentration resulted in an REM of 1.5. 
 1 2 3 4 5 6 7 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 2 1.5 1.4 1 1.5 1.4 1.3 REM 
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5.1.2 Assessment of carbamylation 
The degree of carbamylation of HDL and LDL samples was determined by a 
colorimetric method using diacetyl monoxime as described in cpt 4.2.5. HDL and LDL 
samples were carbamylated with the respective KCNO concentrations (indicated in 
figure 4 and figure 5) for analysis. 
 
 
Figure 4: Assessment of carbamylation of 
carbamylated (left) and native (right) LDL 
(n=3, mean ± SD, ** p < 0.01, unpaired t-test). 
 
LDL carbamylated with 246.5 mM KCNO had ~3.6 fold more protein bound Hcit 
compared to its native form (0 mM KCNO, figure 4). 
 
 
Figure 5: Assessment of carbamylation of 
carbamylated and native HDL 
(n=3, mean ± SD). 
 
Furthermore, HDL carbamylated with different concentrations of KCNO was analyzed 
(figure 5). Here, protein bound Hcit increased with increasing KCNO concentrations 
used for carbamylation. Native HDL and native LDL showed similar degrees of 
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carbamylation (both ~20 µmol Hcit/g protein). However, the highest KCNO 
concentration used during carbamylation resulted in an higher degree of carbamylation 
(~2.5 fold) of HDL compared to LDL. Both, the results obtained from gel 
electrophoresis and colorimetric assay confirm that the in vitro carbamylation 
procedure was effective. 
5.2 Effect of carbamylated LDL on macrophage cholesterol efflux 
To investigate whether incubation with cLDL induces a change in cholesterol efflux as 
compared to nLDL as response to excessive cholesterol uptake, THP-1 macrophages 
and HMDM were incubated with 50 µg/ml cLDL or nLDL for 48 hours. Cells were trace-
labeled with [³H]-cholesterol for measurement of cholesterol efflux to the cholesterol 
acceptors apoA-I, HDL and serum. 
5.2.1 Cholesterol efflux from THP-1 macrophages incubated with cLDL 
Cholesterol efflux to apoA-I was significantly increased in THP-1 macrphages treated 
with cLDL compared to nLDL treated THP-1 cells as depicted in figure 6. In contrast, 
efflux to HDL or serum did not differ between treatments. However, a trend to a 
decreased efflux of cLDL treated THP-1 cells might be recognized to both cholesterol 
acceptors, HDL and serum. It has to be noticed, that among the cholesterol acceptors 
studied, most cholesterol (~35 % of total radioactivity) was transported to serum which 
comprises many cholesterol acceptors. Among them is apoA-I which accounts for 
~2-5 % (of total radioactivity) cholesterol uptake. 
 
   
 
 
Figure 6: Cholesterol efflux from THP-1 macrophages incubated with nLDL and cLDL 
Left panel: efflux to 10 µg/ml apoA-I, middle panel: efflux to 10 µg/ml HDL, right panel: efflux to 1 % 
serum (n=3, mean ± SD, * p < 0.05, unpaired t-test). 
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5.2.2 Cholesterol efflux from HMDM incubated with cLDL 
To confirm the data obtained with THP-1 macrophages, cholesterol efflux experiments 
using HMDM were performed under the same conditions. Treatment of HMDM with 
cLDL as compared to nLDL neither influenced cholesterol efflux to HDL nor to serum 
(figure 7). HMDM, which were treated with cLDL, tended to show an increased efflux to 
apoA-I in comparison to nLDL treated cells, even though this effect was not significant. 
 
   
 
 
Figure 7: Cholesterol efflux from human monocyte-derived macrophages incubated with nLDL and cLDL 
Left panel: efflux to 10 µg/ml apoA-I, middle panel: efflux to 10 µg/ml HDL, right panel: efflux to 1 % 
serum (n=3, mean ± SD). 
 
5.3 Effect of carbamylated and native LDL on ABCA1, ABCG1, 
SR-BI and LXRα expression in THP-1 macrophages 
Incubations of THP-1 macrophages with cLDL increased the cholesterol efflux to 
apoA-I (cpt 5.2.1) but not to HDL or serum. For validation of any dose-dependent 
effects of cLDL and/or nLDL on ABCA1, ABCG1, SR-BI and LXRα mRNA and protein 
expression, THP-1 macrophages were incubated with 12.5, 25, 50 or 100 µg/ml of 
cLDL or nLDL for 48 hours. BSA (2 mg/ml) incubation was used as control. For 
evaluation, values obtained from control incubations (BSA) were set to 100 % for 
Western blot and RQ 1 for qPCR results. 
5.3.1 Effect of carbamylated and native LDL on ABCA1 expression 
A significant difference between nLDL and cLDL treatment on ABCA1 expression 
could be recognized only on the mRNA level (figure 8, left panel) measured by 
quantitative real-time PCR. Four independent incubation experiments showed that 
cLDL incubation markedly increased ABCA1 mRNA compared to nLDL incubation. 
ABCA1 mRNA was increased ~1.4 fold when cells were treated with 12.5 µg/ml cLDL 
and ~1.8 fold when incubated with 100 µg/ml, whereas nLDL treatment did not change 
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mRNA expression compared to control. This effect seemed to be dose-dependent 
within the investigated range (from 12.5 to 100 µg/ml LDL) as increasing 
concentrations of cLDL led to moderately increasing ABCA1 mRNA concentrations. 
Considering ABCA1 protein expression measured by Western blot, the obtained 
results were ambiguous and not statistically significant. However, a trend towards an 
increase in ABCA1 protein expression was apparent as indicated in figure 8 (right 
panel). This trend could be seen already when THP-1 macrophages were incubated 
with a concentration of 25 µg/ml cLDL. 
 
 
 
Figure 8: Effect of different concentrations of cLDL and nLDL on ABCA1 mRNA and protein expression 
in THP-1 macrophages 
left panel: mRNA expression (n=4, mean± SD, * p < 0.05, ** p < 0.01, two-way ANOVA), right panel: 
protein expression (n=3, mean ± SD) and representative Western blot image  
 
Furthermore, ABCA1 protein expression was measured by Western blot analysis in 
HMDM. HMDM obtained from three healthy adult volunteers were incubated under the 
same conditions as THP-1 cells. However, when analyzing ABCA1 protein expression, 
no differences between treatments could be observed and the results were 
inconsistent with high standard deviations (results not shown). Therefore, it was not 
possible to confirm the findings obtained in THP-1 macrophages. 
0 12.5 25 50 100 12.5 25 50 100 
 nLDL cLDL 
ABCA1 
 
β-actin 
 
µg/ml 
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5.3.2 Effect of carbamylated and native LDL on ABCG1 expression 
Similar to ABCA1 mRNA expression, ABCG1 mRNA was increased when THP-1 cells 
were incubated with cLDL compared to nLDL as shown in figure 9 (left panel). Here, all 
cLDL concentrations studied led to a statistically significant increase in ABCG1 mRNA 
when analyzed by two-way ANOVA. Whereas increasing concentrations of nLDL did 
not increase ABCG1 mRNA, it was elevated ~1.6 fold at the lowest (12.5 µg/ml) cLDL 
concentration and slightly increased up to ~1.9 fold when incubated with 100 µg/ml 
cLDL. 
In contrast to the qPCR experiments, Western blot analysis of ABCG1 protein (figure 
9, right panel) gave different results. Here, THP-1 macrophages incubated with both, 
12.5 µg/ml nLDL or cLDL resulted in a similar protein expression of ABCG1. Contrary 
to the qPCR results, nLDL seemed also to influence ABCG1 protein expression, as all 
nLDL concentrations studied increased ABCG1 protein. Nevertheless, cLDL may have 
a stronger impact on ABCG1 protein expression than nLDL. Incubation with increasing 
cLDL concentrations increased the expression of ABCG1 stronger as compared to 
nLDL incubations. In addition, 100 µg/ml cLDL even doubled the amount of ABCG1 
protein compared to control samples (BSA incubation). However, the obtained 
Western blot results were not significant. 
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Figure 9: Effect of different concentrations of cLDL and nLDL on ABCG1 mRNA and protein expression 
in THP-1 macrophages 
left panel: mRNA expression (n=4, mean± SD, *** p < 0.001, two-way ANOVA), right panel: protein 
expression (n=3, mean ± SD) and representative Western blot image 
 
ABCG1 protein expression was also measured in HMDM obtained from three healthy 
volunteers. Cells were incubated under the same conditions as described above. 
Western blot analysis (not shown) could partly confirm the results achieved with THP-1 
macrophages. In contrast to THP-1 macrophages, increasing cLDL concentrations 
increased ABCG1 protein as compared to nLDL incubation in HMDM. Furthermore, 
treatment of HMDM with nLDL did not change protein expression. Even though the 
results had high standard deviations and were not significant, a trend towards 
increasing ABCG1 protein expression with cLDL incubation could be recognized. 
5.3.3 Effect of carbamylated and native LDL on SR-BI expression 
THP-1 macrophages showed an increase in SR-BI mRNA when incubated with both, 
nLDL and cLDL. The effect was analyzed via one-way ANOVA and all LDL incubations 
increased (p <0.001) SR-BI mRNA compared to control incubation in the absence of 
LDL. Moreover, this effect did not appear to be dose-dependent and all incubations 
with the concentrations studied led to a similar result, namely upregulation of SR-BI 
mRNA. 
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We observed a different outcome after analyzing SR-BI protein expression by Western 
blot experiments. Neither nLDL nor cLDL changed the SR-BI protein concentration at 
lower concentrations (from 12.5 to 50 µg/ml). However, incubations with 100 µg/ml 
cLDL tended to increase SR-BI protein. This trend, however, was not significant. 
 
 
 
Figure 10: Effect of different concentrations of cLDL and nLDL on SR-BI mRNA and protein expression 
in THP-1 macrophages 
left panel: mRNA expression (n=4, mean± SD, * p < 0.05, two-way ANOVA), right panel: protein 
expression (n=3, mean ± SD) and representative Western blot image 
 
SR-BI protein expression also was measured by Western blot analysis in HMDM 
incubated with different concentrations of nLDL and cLDL. The results obtained were 
inconsistent and the different HMDM preparations yielded inconsistent data for SR-BI 
protein (not shown). The findings obtained in THP-1 macrophages could not be 
confirmed for that reason. 
5.3.4 Effect of carbamylated and native LDL on LXRα expression 
LXRα expression was determined on an mRNA level via qPCR. Incubation of THP-1 
macrophages with nLDL did not alter LXRα mRNA expression as compared to control 
(figure 11). Moreover, low doses of cLDL did not change LXRα mRNA as well. We 
could find a significant effect of cLDL only when THP-1 macrophages were incubated 
with a high concentration (100 µg/ml). Here, THP-1 macrophages treated with 
100 µg/ml cLDL showed a 3-fold increase in LXRα mRNA as compared to control. 
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Figure 11: Effect of different concentrations of cLDL 
and nLDL on LXRα mRNA expression in THP-1 
macrophages 
(n=4, mean ± SD, ** p < 0.01, two-way ANOVA) 
 
5.4 Effect of the LXR antagonist GGPP on ABCA1, ABCG1 and 
SR-BI protein expression in THP-1 macrophages incubated 
with cLDL and nLDL 
To determine whether the effects of cLDL on ABCA1, ABCG1 and SR-BI are at least in 
part mediated by LXR, cLDL and nLDL incubated THP-1 macrophages were treated 
with geranyl-geranyl-pyrophosphate (GGPP) to antagonize LXR (Gan et al., 2001). 
Therefore, THP-1 macrophages were incubated with 50 µg/ml cLDL or nLDL for 48 
hours. BSA (2 mg/ml) incubation was used as control. 10 µM GGPP was added to the 
cells 24 hours prior to cell lysis.. As GGPP is dissolved in methanol, control 
incubations without GGPP were performed where cells were treated with the same 
volume (i.e. 6.76 µl in 1.5 ml medium) of methanol instead of GGPP. After cell lysis, 
Western blot analysis was performed and the protein expression of BSA treated THP-1 
macrophages without GGPP incubation was set to 100 %. 
Even though we could observe that GGPP tended to decrease ABCA1 protein to 
~80 % of control (BSA incubation), the obtained results were not significant. 
Furthermore, GGPP did not change ABCA1 protein expression in THP-1 macrophages 
treated with both, nLDL or cLDL (figure 12). 
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Figure 12: Effect of GGPP on ABCA1 protein 
expression in THP-1 macrophages 
(n=2, mean ± SD) 
 
Similarly, Western blot analysis of ABCG1 protein expression (figure 13) of THP-1 
macrophages with the same treatments did not show a significant change when cells 
were incubated with or without GGPP. 
 
 
Figure 13: Effect of GGPP on ABCG1 protein 
expression in THP-1 macrophages 
(n=2, mean ± SD) 
 
Considering SR-BI, GGPP did not appear to influence its expression as illustrated in 
figure 14. No differences between incubations with or without GGPP could be 
observed. 
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Figure 14: Effect of GGPP on SR-BI protein expression 
in THP-1 macrophages 
(n=2, mean ± SD) 
 
5.5 Effect of blocking ABCA1 by probucol on cholesterol efflux in 
THP-1 macrophages incubated with cLDL and nLDL 
As cLDL induced an increased cholesterol efflux to apoA-I in THP-1 macrophages (cpt. 
5.2.1), it was of interest, whether this increase was mediated by ABCA1 and thus, 
could be inhibited by probucol. Probucol is a substance supposed to inhibit ABCA1-
mediated cholesterol efflux by inhibiting the translocation of ABCA1 to the plasma 
membrane (Favari et al., 2004). For this purpose, cholesterol efflux to apoA-I, HDL and 
serum from cLDL, nLDL or BSA treated THP-1 macrophages with or without probucol 
was measured. 
Compared to BSA and nLDL incubation of THP-1 macrophages, cLDL increased the 
cholesterol efflux to apoA-I. However, figure 15 demonstrates that probucol was not 
able to counteract this effect. Furthermore, probucol had no significant effect on 
apoA-I-mediated cholesterol efflux in cells incubated with BSA and nLDL. 
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Figure 15: Effect of probucol on cholesterol efflux from 
THP-1 macrophages incubated with BSA, nLDL or 
cLDL to apoA-I 
Efflux to 10 µg/ml apoA-I (n=4, mean ± SD). 
 
In addition, cholesterol efflux to HDL and serum was measured under the same 
conditions. The cholesterol efflux to both acceptors was unaltered when cells were 
exposed to probucol as illustrated in figure 16. 
 
 
 
Figure 16: Effect of probucol on cholesterol efflux from THP-1 macrophages incubated with BSA, nLDL 
or cLDL to serum or HDL 
Left panel: efflux to 10 µg/ml HDL, right panel: efflux to 1 % serum (n=4, mean ± SD). 
 
To provide evidence of the effectiveness of probucol in THP-1 macrophages on 
cholesterol efflux, further experiments using cholesterol loaded cells were performed 
as originally described by Favari et al., 2004. Macrophages were treated with acLDL to 
induce extensive intracellular cholesterol accumulation and with a synthetic LXR-
agonist to upregulate cholesterol efflux transporters. Control incubations were 
performed in the absence of LXR-agonist. Cholesterol efflux to apoA-I, HDL or serum 
was measured after probucol incubation. 
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Probucol reduced the cholesterol efflux to apoA-I in THP-1 cells only when LXR was 
stimulated (figure 17, right panel). In cells without LXR-agonist treatment (left panel), 
probucol had no effect on the efflux to apoA-I. Moreover, cholesterol efflux to HDL and 
serum was studied under the same conditions. Here, probucol did not influence 
cholesterol efflux. 
 
 
 
Figure 17: Effect of probucol on cholesterol efflux from acLDL-loaded THP-1 macrophages to apoA-I, 
HDL and serum 
Left panel: cells without LXR-agonist treatment, right panel: cells with LXR-agonist treatment (n=3, mean 
± SD). 
 
5.6 Analysis of ABCA1, ABCG1, SR-BI and LXRα during THP-1 
differentiation 
In differentiated macrophages, LXRα regulates the expression of ABCA1, ABCG1 and 
SR-BI (Tontonoz et al., 2003; Hu et al., 2010). To determine whether this also occurs 
during differentiation, we tested whether LXRα mRNA expression correlates with 
ABCA1, ABCG1 and SR-BI expression during THP-1 differentiation. 
For characterization of the change in expression of ABCA1, ABCG1, SR-BI and LXRα 
during THP-1 differentiation, THP-1 monocytes were differentiated with PMA towards 
macrophages. RNA and proteins were isolated at day 0, 1, 2 and 3 of differentiation for 
their further analysis. Day 0 represents the monocytic state and at day 3, THP-1 
macrophages were fully differentiated. For evaluation, values obtained on day 0 were 
set to 100 % for Western blot and to RQ 1 for qPCR results. 
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5.6.1 ABCA1 mRNA and protein expression during THP-1 differentiation 
ABCA1 mRNA expression increased during differentiation as depicted in figure 18. A 
twofold increase of ABCA1 mRNA could be observed in differentiated THP-1 
macrophages (day 3) compared to THP-1 monocytes (day 0). Considering ABCA1 
protein expression, the same trend could be noticed and differentiated cells expressed 
even 2.7 fold more ABCA1 protein than undifferentiated cells. 
 
 
 
Figure 18: ABCA1 mRNA and protein expression during THP-1 differentiation 
left panel: mRNA expression (n=2, mean ± SD, ** p < 0.01, one-way ANOVA, compared to day 0), right 
panel: protein expression (n=2, mean ± SD, * p < 0.05, one-way ANOVA, compared to day 0) and 
representative Western blot image 
 
5.6.2 ABCG1 mRNA and protein expression during THP-1 differentiation 
When characterizing ABCG1 expression, both, mRNA and protein (figure 19) did not 
differ between between differentiated THP-1 macrophages and undifferentiated THP-1 
monocytes but a transient decrease of ABCA1 mRNA could be observed on day 1 and 
day 2 of differentiation. However, ABCG1 protein expression did not change 
significantly during THP-1 differentiation. 
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Figure 19: ABCG1 mRNA and protein expression during THP-1 differentiation 
left panel: mRNA expression (n=3, mean ± SD, *** p < 0.01, one-way ANOVA, compared to day 0), right 
panel: protein expression (n=2, mean ± SD) 
 
5.6.3 SR-BI mRNA and protein expression during THP-1 differentiation 
SR-BI mRNA and protein decreased with proceeding differentiation of THP-1 cells as 
schematized in figure 20. When comparing mRNA and protein expressed during the 
different time points with the expression on day 0, a significant change could be 
noticed. The decrease appeared more pronounced for mRNA than for protein: mRNA 
was reduced by 86 % whereas protein was decreased by 68 % in differentiated THP-1 
macrophages compared to the expression on day 0. 
 
 
 
Figure 20: SR-BI mRNA and protein expression during THP-1 differentiation 
left panel: mRNA expression, right panel: protein expression (n=2, mean ± SD, * p < 0.05, ** p < 0.01, 
*** p < 0.001, one-way ANOVA, compared to day 0) 
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5.6.4 LXRα mRNA expression during THP-1 differentiation 
Our results show that the level of LXRα mRNA remained unchanged (figure 21) during 
THP-1 differentiation and hence, did not correlate with either ABCA1, ABCG1 or SR-BI 
expression. 
 
 
 
 
 
Figure 21: LXRα mRNA expression during THP-1 
differentiation 
(n=2, mean ± SD) 
 
5.7 Effect of modified LDL on miRNA expression in THP-1 
macrophages 
THP-1 macrophages showed an increased SR-BI mRNA expression when incubated 
with both, nLDL and cLDL (cpt. 5.3.3). Therefore, we examined, whether the 
expression of miR-223, which is predicted to target SR-BI mRNA (Vickers et al., 2011), 
correlates with these observations. Moreover, we observed that cLDL significantly 
increased ABCA1 mRNA expression (cpt. 5.3.1) and hence, we hypothesized that 
miR-33a expression in cells incubated with cLDL may be lowered because miR-33a 
targets ABCA1 mRNA (Rayner et al., 2010). To address these questions, the 
expression of miR-223 and miR-33a was measured in THP-1 macrophages incubated 
with modified forms of LDL (50 µg/ml) for 48 hours. In addition to nLDL and cLDL, also 
oxLDL and acLDL were used in the incubation experiments to study their influence on 
miR-223 and miR-33a level in THP-1 macrophages. BSA (2 mg/ml) incubation was 
used as control. 
As illustrated in the left panel of figure 22, both, cLDL and nLDL induced a ~10 % lower 
expression of miR-223 compared control incubation (BSA), which was set to an RQ 
value of 1 (represented by the dotted line). Furthermore, miR-223 expression was 
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increased in oxLDL and acLDL treated cells. However, the changes to control 
incubations were small and thus, represent rather a trend than a clear effect. The right 
panel shows miR-33a expression in THP-1 macrophages incubated with modified 
LDLs. No difference of miR-33a expression could be observed between treatments. 
 
 
 
Figure 22: miR-223 and miR-33a expression in THP-1 macrophages incubated with nLDL, cLDL, oxLDL 
or acLDL 
left panel: miR-223 expression (n=2, mean ± SD, * p < 0.05, ** p < 0.01, one-way ANOVA, compared to 
control incubation), right panel: miR-33a expression (n=2, mean ± SD); the dotted line represents the 
expression of the reference sample (BSA incubation) for which the RQ value was set to 1. 
 
5.8 Cholesterol acceptor capacity of cHDL 
Increased plasma urea levels, caused by CRF lead to increased carbamylation of 
proteins (Wang et al., 2007b). Therefore, we asked whether the ability of HDL to 
accept cholesterol is altered when it is carbamylated. 
5.8.1 Capacity of cHDL to accept cellular cholesterol from THP-1 macrophages 
Cholesterol efflux from THP-1 macrophages was measured to native HDL and in vitro 
carbamylated HDL with different degrees of carbamylation. To obtain various HDL 
preparations with different degrees of carbamylation, two different approaches were 
used. First, different concentrations of KCNO were used in individual carbamylation 
reactions of HDL. Second, one HDL sample was carbamylated and further diluted 
stepwise with native HDL to obtain HDL samples with different amounts of 
carbamylated particles. In both approaches, the highest carbamylated HDL sample 
was produced with the same concentration of KCNO (246.5 mM). Efflux was measured 
from cholesterol-loaded (acLDL) THP-1 macrophages treated with an LXR-agonist.. 
Cholesterol efflux to cHDL did not differ from efflux to nHDL as shown in figure 23, 
irrespective of the degree of HDL carbamylation. Both cholesterol efflux experiments 
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with carbamylated HDL samples yielded similar results. Therefore, the cholesterol 
acceptor capacity of HDL seemed to be independent of its carbamylation status. 
 
 
 
Figure 23: Cholesterol acceptor capacity of cHDL (THP-1 macrophages) 
top panel: efflux to individually carbamylated HDL samples, (n=2, mean ± 
SD), values on the x-axis represent measured degrees of carbamylation 
(cpt.5.1.2); bottom panel: efflux to cHDL, stepwise diluted with nHDL 
(n=2, mean ± SD) 
 
5.8.2 Capacity of cHDL to accept cellular cholesterol from HMDM 
To confirm the results obtained with THP-1 macrophages, cholesterol efflux to cHDL 
and nHDL from cholesterol-loaded (acLDL) HMDM treated with an LXR-agnoist was 
measured. In HMDM, the cholesterol efflux capacity of HDL tended to decrease when 
it was carbamylated (figure 24). However, statistical analysis of the reduced 
cholesterol acceptor capacity of cHDL using HMDM as cell model reached no 
significance. Therefore, carbamylation may not impair the cholesterol acceptor 
capacity of HDL. 
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Figure 24: Cholesterol acceptor capacity of cHDL 
(HMDM) 
(n=4, mean ± SD) 
 
5.9 Cholesterol acceptor capacity of serum from CRF- and 
hemodialysis patients 
We studied whether the cholesterol acceptor capacity of serum in renal disease is 
altered compared to serum of healthy subjects. For this purpose, cholesterol efflux to 
serum of patients with CRF (n=17) and to serum of patients with ESRD on 
hemodialysis treatment (n=14) was measured using cholesterol-loaded (acLDL) THP-1 
macrophages incubated with an LXR-agonist. Furthermore, efflux was measured to 
serum from healthy matched individuals (n=17 and n=14, respectively). 
The cholesterol acceptor capacity of serum from CRF-patients was significantly 
(p < 0.05) higher than those of healthy controls, albeit this difference (3.5 %) was very 
small (figure 25, left panel). In contrast, serum of ESRD-patients on hemodialysis 
treatment had a diminished cholesterol acceptor capacity (5 %) compared to serum of 
matched controls (p < 0.001) as shown in figure 25 (right panel). 
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Figure 25: Cholesterol acceptor capacity of serum from CRF- and hemodialysis patients using THP-1 
macrophages 
left panel: efflux to serum of CRF-patients and matched controls (n=17, mean ± SD, * p < 0.05, unpaired 
t-test), right panel: efflux to serum of ESRD-patients and matched controls (n=14, mean ± SD, *** p < 
0.001, unpaired t-test) 
 
To confirm the results obtained with THP-1 macrophages, experiments were 
performed in which cholesterol efflux was measured from acLDL-loaded HMDM 
treated with an LXR-agonist to pooled serum of patients with CRF and ESRD-patients 
on hemodialysis treatment and matched controls. 
As shown in figure 26, the cholesterol acceptor capacity of pooled serum from both, 
CRF-patients and ESRD-patients on hemodialysis treatment, did not differ as 
compared to serum of controls and hence, the results shown in figure 25 could not be 
confirmed in HMDM. 
 
 
 
Figure 26: Cholesterol acceptor capacity of serum from CRF- and hemodialysis patients using HMDM 
left panel: efflux to pooled serum of CRF-patients and controls (n=4, mean ± SD) right panel: efflux to 
pooled serum of ESRD-patients and controls (n=4, mean ± SD) 
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6 Discussion 
Patients suffering from CRF are highly susceptible to atherosclerosis. In spite of known 
risk factors like enhanced oxidative stress, inflammation or dyslipidemia (reviewed by 
Vaziri et al., 2011) the increased incidence of atherosclerosis in CRF-patients is not 
fully understood. CRF-patients have elevated levels of plasma urea (Kraus et al., 
2001). The active form of cyanate, isocyanic acid, is derived from urea and chemically 
modifies proteins by carbamylation, thereby altering the structure and functional 
properties of proteins. The formation of isocyanic acid is promoted by increased blood 
urea levels as found in patients suffering from CRF (Jaisson et al., 2011). In this 
context, the apolipoproteins of LDL and HDL are prone to carbamylation (Gonen et al., 
1985; Holzer et al., 2011). Furthermore, it has been described that CRF-patients have 
increased plasma cLDL-levels (Apostolov et al., 2005). It is known, that modified forms 
of LDL are taken up nonspecifically by arterial macrophages via several scavenger 
receptors and that this nonspecific uptake leads to the formation of foam cells (for 
review see Moore et al., 2011). However, the molecular mechanisms underlying the 
effect of cLDL on macrophages are poorly understood. 
In this study, we tried to elucidate the effects of cLDL on human macrophages using 
THP-1 cells and human monocyte-derived macrophages. LDL isolated from healthy, 
normolipidemic volunteers was carbamylated in vitro. To ensure proper carbamylation, 
the relative electrophoretic mobility (REM) as well the degree of carbamylation was 
evaluated. With these measurements we could confirm that LDL was carbamylated 
appropriately based on the charge alteration of cLDL (REM of 2). Furthermore, a 
colorimetric assay was performed to measure the degree of carbamylation of LDL. 
Again, we could confirm appropriate carbamylation of the LDL preparations, which 
were used throughout further experiments. According to the measurements, cLDL 
contained ~3.6 fold more protein bound homocitrulline than nLDL. 
Carbamylated LDL lacks the ability to bind to the LDL-receptor. In contrast, cLDL is 
mostly recognized by scavenger receptors (for review see Basnakian et al., 2010), 
preferably SR-A, and it is taken up in a nonspecific and unregulated manner (Wang et 
al., 2007b). We studied the effect of cLDL on the cholesterol efflux capacity of human 
macrophages. There was no significant difference in cholesterol efflux to serum or 
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HDL after incubation with cLDL compared to nLDL. However, a significant increase in 
cholesterol efflux to apoA-I could be observed when THP-1 macrophages were treated 
with cLDL compared to nLDL. Cholesterol efflux to apoA-I is mediated by ABCA1 and 
indeed, ABCA1 mRNA was increased in the presence of cLDL as discussed below. 
This could explain the elevated cholesterol efflux to apoA-I from cLDL treated THP-1 
macrophages. Even so, the cholesterol efflux to apoA-I represents ~10 % of the total 
cholesterol efflux to serum, which contains a wide spectrum of cholesterol acceptors 
such as lipoproteins and apolipoproteins. In an attempt to confirm the results obtained 
with THP-1 cells, LDL incubations and cholesterol efflux experiments were performed 
under the same conditions using human monocyte-derived macrophages (HMDM). 
With HMDM, however, it was not possible to obtain significant results due to high 
standard deviations. Anyhow, a trend towards an increased cholesterol efflux from 
HMDM to apoA-I was found after cLDL incubation as compared to nLDL. The elevated 
cholesterol efflux to apoA-I after cLDL-treatment prompted us to further investigate 
several efflux transporters of macrophages on the mRNA and protein level, and to ask, 
whether there are any dose-dependent effects of nLDL or cLDL on the expression of 
these transporters. 
Quantitative real-time PCR experiments showed, that ABCA1 and ABCG1 mRNA 
expression of nLDL-treated THP-1 macrophages was unaltered compared to control 
incubation (without LDL). Neither the lowest (i.e. 12.5 µg/ml) nor the highest (i.e. 
100 µg/ml) nLDL concentration studied altered the mRNA expression of these ABC 
transporters. Our findings differ from those of some other groups. The studies of Zhu et 
al., 2005, and Chen et al., 2011, resulted in an increase of ABCA1 expression when 
macrophages were treated with nLDL. However, Chen and his group did not use 
human but mouse macrophages and the group of Zhu incubated THP-1 macrophages 
with 1.8 mg/ml nLDL and found a small increase in ABCA1 mRNA. The highest 
concentration we have used in our experiments was much lower, namely 100 µg/ml. In 
contrast to the results obtained with nLDL, we could show that cLDL-treated THP-1 
macrophages had elevated levels of ABCA1 and ABCG1 mRNA even when cells were 
incubated with low (12.5 µg/ml) cLDL concentrations. Furthermore, the mRNA levels 
significantly increased with increasing cLDL concentrations. Western blot experiments 
were performed to measure ABCA1 and ABCG1 protein expression from THP-1 
macrophages treated with different concentrations of nLDL or cLDL. These 
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experiments produced no significant results due to high standard deviations, but also 
here, a clear trend towards an increase of ABCA1 and ABCG1 protein expression was 
found. nLDL did not appear to influence ABCA1 protein expression. Contrary to the 
qPCR results, nLDL incubation resulted in an increase of ABCG1 protein expression, 
even though the effect was not as strong as the cLDL-induced elevation. ABCA1 and 
ABCG1 protein expression was also measured in cLDL and nLDL-treated HMDM, but 
the experiments did not produce significant differences. However, in these cells too, 
we could find a trend towards a cLDL-induced elevation of the protein levels of ABCA1 
and ABCG1. 
The receptor SR-BI, which is located in the plasma membrane, is highly expressed in 
the liver. There, it mediates the terminal step of RCT, namely uptake of HDL 
cholesterol. Beyond that, SR-BI is also expressed in macrophages and it is supposed 
to be involved in the cholesterol efflux from these cells (for review see Moore et al., 
2006). However, the role of SR-BI in the first part of RCT is not well defined and the 
findings of several studies are controversial. The group of Wang demonstrated, that 
SR-BI is not involved in macrophage RCT in mice in vivo (Wang et al., 2007a). They 
proposed that primarily ABCA1 and ABCG1 contribute to this mechanism. In contrast, 
Zhao et al., 2010, showed that in ABCA1/SR-BI double knockout mice macrophage 
foam cell formation is enhanced as compared to single knockout mice, indicating that 
SR-BI and ABCA1 act synergistically to regulate cholesterol homeostasis in 
macrophages in mice in vivo. 
Hirano et al., 1999, demonstrated that SR-BI mRNA and protein is increased in HMDM 
after acLDL or oxLDL incubation. To determine the role of cLDL on SR-BI macrophage 
RCT, we aimed to identify, whether incubation with cLDL alters the expression of 
SR-BI in human macrophages. Therefore, we determined the mRNA and protein 
expression of SR-BI in cLDL- and nLDL-incubated THP-1 macrophages. In our 
experiments, the SR-BI mRNA level doubled when cells were incubated with either 
nLDL or cLDL compared to incubation without LDL. Hence, these results suggest that 
LDL in general, irrespective of whether it is carbamylated or not, increases SR-BI 
mRNA. We could not find any dose-dependent effects of cLDL and nLDL on SR-BI 
expression as there was no difference in the mRNA levels between low-dose 
(12.5 µg/ml) and high-dose (100 µg/ml) treatments. In contrast, the results obtained 
from Western blot experiments were different. Here, the SR-BI protein concentration 
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was slightly increased when cells were incubated with 100 µg/ml cLDL or nLDL, while 
incubations with lower doses of cLDL or nLDL did not alter SR-BI protein. SR-BI 
protein levels do not always correlate with those of SR-BI mRNA (Stangl et al., 2002), 
which may indicate that SR-BI is highly regulated on a translational or post-
translational level. 
The nuclear receptor LXRα is involved in the control of cellular lipid homeostasis. LXRs 
act as cholesterol sensors in cells and regulate the expression of several genes 
involved in the efflux of cholesterol (Tontonoz et al., 2003). It is commonly accepted, 
that LXR activation increases ABCA1 (Schwartz et al., 2000; Venkateswaran et al., 
2000) and ABCG1 gene expression (Wang et al., 2006), but its role on SR-BI 
expression is controversial. Several authors identified LXR as an important regulator of 
SR-BI in their studies (Malerod et al., 2002; Hu et al., 2010), while others do not 
support this idea (Yu et al., 2004; Bultel et al., 2008). We studied the mRNA 
expression of LXRα from cLDL- and nLDL-treated THP-1 macrophages to find a 
possible link to the cLDL-induced elevation of ABCA1 and ABCG1 mRNA and the 
LDL-induced increase in SR-BI mRNA. In fact, LXRα mRNA expression increased 
when cells were incubated with increasing concentrations of both, cLDL and nLDL. 
However, cLDL incubation significantly increased LXRα mRNA compared to nLDL 
incubation only in THP-1 macrophages incubated with high concentrations of LDL 
(100 µg/ml). According to these results it appeared possible, that LXRα is involved in 
the cLDL-induced elevation of ABCA1 and ABCG1 expression. In order to test this 
hyposthesis, we measured ABCA1, ABCG1 and SR-BI protein expression in THP-1 
macrophages which were preincubated with an LXR-antagonist (GGPP). We did not 
see an effect of GGPP on the cLDL-mediated expression of the proteins studied and 
therefore it is likely, that not only LXRα but also other factors mediate their regulation. 
Favari et al., 2004, demonstrated that probucol inhibits ABCA1-mediated lipid efflux. 
Since our research showed, that cLDL-treated macrophages had an increased 
cholesterol efflux to apoA-I compared to nLDL-treated cells, we tried to antagonize this 
effect by blocking ABCA1 with probucol. In addition, we studied, whether probucol 
impairs the cholesterol efflux to HDL or serum. However, in our experiments, we could 
not detect any effect of probucol on cholesterol efflux, neither to apoA-I nor to HDL or 
serum. In order to demonstrate that our probucol preparation was active, we evaluated 
its effect on cholesterol-loaded (acLDL) THP-1 macrophages. Here, probucol 
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effectively lowered the cholesterol efflux to apoA-I, but only when LXR was activated 
using a synthetic LXR-agonist. Compared to the effect of the LXR-agonist, which 
elevates the cholesterol efflux to apoA-I from 5 % to 13 %, the effect of cLDL is much 
smaller (from 2 % to 5 %). Hence, the cLDL-induced raise of the ABCA1-mediated 
cholesterol efflux may not be robust enough to be inhibited by probucol in a noticeable 
manner. 
Even though we could show in THP-1 macrophages, that cLDL enhances 
apoA-I-mediated cholesterol efflux and it upregulates several cholesterol efflux 
transporters, this mechanisms do not seem to counteract the imbalance between 
cholesterol influx and efflux of cholesterol because cLDL induces foam cell formation 
as we have observed under the microscope (not shown). 
It is commonly accepted, that LXRα is an important regulator of the gene expression of 
ABCA1, ABCG1 (reviewed by Tall, 2008) and possibly SR-BI (Malerod et al., 2002; Hu 
et al., 2010). Furthermore, it is known that ABCA1 mRNA expression increases during 
macrophage differentiation (Kielar et al., 2001; Langmann et al., 2003). Thus, we 
hypothesized that the mRNA expression of LXRα may correlate with that of ABCA1, 
ABCG1 and SR-BI during THP-1 differentiation. Therefore, we characterized the 
expression of ABCA1, ABCG1, SR-BI and LXRα during THP-1 differentiation by qPCR 
experiments. Whereas the LXRα expression remained unchanged during THP-1 
differentiation, we could clearly demonstrate, that ABCA1 expression increases with 
proceeding differentiation. This may indicate that the upregulation of ABCA1 in this 
situation is independent of LXRα expression. In contrast, the ABCG1 expression on 
day 0 was similar to the expression on day 3 and on the days between, ABCG1 was 
downregulated. The reason for the downregulation of ABCG1 on day 1 and day 2 is 
unclear. It might be due to e.g. a direct action of PMA, the substance used for in vitro 
differentiation (Tsuchiya et al., 1982). We also investigated the SR-BI expression 
under the same conditions. Our studies showed that SR-BI expression decreased 
during differentiation. This finding supported those of Murao et al., 1997, who also 
found decreasing levels of SR-BI during THP-1 differentiation. However, Hirano et al., 
1999, studied the SR-BI expression during the differentiation of HMDM, without the 
use of PMA, and their results indicated an increase in SR-BI expression with 
proceeding differentiation. An explanation for this contradictory results is lacking but 
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since PMA is not an endogenous molecule for differentiation initiation, it may induce 
signal transduction cascades which differ from those during in vivo differentiation.  
The expression levels of ABCA1, ABCG1 and SR-BI were altered when cells were 
incubated with cLDL as compared to control. However, cLDL incubation did not induce 
an increase in LXRα mRNA. Thus, it is likely, that other factors may predominate the 
regulation of these proteins. Among the possible candidates, we studied the 
expression of two particular miRNAs, which negatively regulate ABCA1 and SR-BI. 
MiR-33a is predicted to target ABCA1 mRNA and thereby lowers its expression 
(Rayner et al., 2010). However, our hypothesis that the cLDL-induced elevation of 
ABCA1 might be due to a decreased miR-33a expression level could not be confirmed 
by our experiments. Moreover, the other modified LDLs studied (i.e. acLDL and 
oxLDL), did not alter miR-33a expression either compared to the control incubation 
(BSA). In conclusion, we were not able to show in our experiments, that miR-33a 
expression correlates with the cLDL-induced increase of ABCA mRNA. We also asked, 
whether the expression of miR-223, which is predicted to target SR-BI mRNA (Vickers 
et al., 2011), correlates with the elevated SR-BI mRNA expression in nLDL- and cLDL-
incubated cells. In fact, our results showed that miR-223 was lowered by about 10 % 
(p < 0.05) compared to control when cells were incubated with nLDL or cLDL. This 
observation might suggest, that native and also carbamylated LDL may negatively 
regulate miR-223 expression and thereby indirectly upregulate SR-BI mRNA. In 
addition, we could show, that acLDL and oxLDL increase miR-223 expression by about 
15 % (p < 0.01). Several studies indicate, that acLDL and oxLDL incubations reduce 
SR-BI expression in macrophages (Lam et al., 2004; Yu et al., 2004) and with our 
results, we further hypothesize, that the increased miR-223 expression may be 
involved in this effect of both modified LDLs. 
Another aim of our study was to determine the cholesterol acceptor capacity of in vitro 
carbamylated HDL compared to native HDL. HDL from healthy, normolipidemic 
volunteers was carbamylated in vitro and similar to cLDL, quality control experiments 
were performed. The electrophoretic mobility of HDL increased when it was 
carbamylated and the colorimetric assay using diacetyl monoxime further provided 
evidence for protein-bound Hcit on the carbamylated HDL samples. cHDL contained 
~12 fold more bound Hcit than nHDL. Compared to the results obtained for the cLDL 
samples, the same amount of KCNO (245.6 mM) used for carbamylation produced 
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different degrees of carbamylation: 75 µmol Hcit/g protein for cLDL and 190 µmol 
Hcit/g protein for cHDL, respectively. A possible explanation for this difference may be 
the different protein composition of these two lipoproteins and the accessibility of their 
lysines to carbamylation. The only protein component of LDL is one molecule of 
apoB-100 (as reviewed by Segrest et al., 2001), and the main apolipoprotein HDL is 
apoA-I (as reviewed by Thomas et al., 2008), both differing considerably in their 
structure, composition and function. ApoB-100 consists of 4563 amino acids, among 
them 356 lysines (Chen et al., 1986) . In contrast, apoA-I is a much smaller protein 
with a primary structure of 243 amino acids and 21 lysine residues (Brouillette et al., 
2001). Hence, both proteins contain a similar lysine content (~8 % lysines) and with 
this information, the higher degree of carbamylation of cHDL compared to cLDL can 
not be explained and remains unclear. 
Patients with CRF have increased plasma urea levels, which lead to carbamylation of 
proteins (Wang et al., 2007b). The apolipoproteins of HDL are susceptible to this 
modification (Holzer et al., 2011), but it is not well studied, whether carbamylation 
alters the cholesterol acceptor capacity of cHDL. Hence, we studied the cholesterol 
acceptor capacity of carbamylated HDL by measuring cholesterol efflux from 
cholesterol-loaded THP-1 macrophages, incubated with a synthetic LXR-agonist, to 
nHDL and to HDL samples with increasing degrees of carbamylation. Our results 
indicated, that the cholesterol acceptor capacity of HDL seems to be independent of its 
degree of carbamylation (from 15 to 186 µmol Hcit/g protein). Holzer and his group 
showed in their publication, that the cholesterol efflux to carbamylated HDL is reduced 
in THP-1 macrophages infected with an adenovirus encoding SR-BI (Holzer et al., 
2011). Cholesterol efflux from control THP-1 macrophages to HDL, however, was 
unaltered when HDL was carbamylated, which is consistent with our study. In addition, 
we performed cholesterol efflux experiments using HMDM to confirm the results 
obtained with THP-1 cells. Here, we observed a slight trend of cHDL towards a lower 
cholesterol acceptor capacity compared to its native form, but the results were not 
significant.  
Finally, we investigated the cholesterol acceptor capacity of serum obtained from 
patients with CRF or from patients with ESRD on hemodialysis treatment and 
respective healthy controls. Cholesterol efflux was measured from cholesterol-loaded 
THP-1 macrophages treated with an LXR-agonist. Here, we could show that serum 
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from CRF-patients had a higher cholesterol acceptor capacity than control serum, even 
though the difference was very small (45 % vs. 49 % cholesterol acceptor capacity). In 
contrast, serum from ESRD-patients on hemodialysis treatment featured a diminished 
cholesterol acceptor capacity compared to the respective control serum and this 
difference was highly significant. ESRD-patients on hemodialysis treatment had 
significantly lower apoA-I as well as HDL levels compared to their controls (see 
supplementary data), which may explain the reduced cholesterol acceptor capacity of 
their serum. 
In conclusion, the nonspecific and excessive uptake of carbamylated LDL by 
macrophages may be compensated in some extent by the upregulation of several 
cholesterol efflux transporters. We could not demonstrate, that carbamylated HDL had 
an altered cholesterol acceptor capacity and thus, cHDL may have a minor role in the 
pathogenesis of atherosclerosis. Nevertheless, the mechanisms by which 
carbamylated LDL alter gene expression are still unknown and further investigations 
are needed. 
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7 Summary 
Atherosclerosis is characterized by atheromatous plaques in the arterial wall that may 
lead to medical complications such as myocardial infarction or stroke. Accelerated 
atherosclerosis is often found in patients with chronic renal failure (CRF). In addition to 
the traditional risk factors for atherosclerosis, CRF-patients have elevated plasma urea 
concentrations, which induce the carbamylation of proteins (such as LDL). 
Carbamylated LDL (cLDL) is taken up by macrophages in a nonspecific and 
unregulated way via scavenger receptors, which leads to an enhanced formation of 
foam cells.  
In this study, we asked whether macrophages can compensate for the increased 
nonspecific uptake of cLDL by increasing cellular cholesterol efflux. Therefore, we 
investigated cLDL-induced changes in macrophage cholesterol efflux and in the 
expression of the transporters mediating this efflux process. We could demonstrate 
that THP-1 macrophages increased the ABCA1-mediated cholesterol efflux to apoA-I 
when they were exposed to cLDL. We could further show, that cLDL induced an 
upregulation of ABCA1, ABCG1, SR-BI and, at higher doses, LXRα in THP-1 
macrophages. Moreover, native LDL also induced an increase in SR-BI and LXRα 
expression. To test whether the cLDL-induced change of ABCA1, ABCG1 and SR-BI 
expression is mediated via LXRα, we treated THP-1 macrophages, which were 
incubated with BSA, nLDL or cLDL, with an LXR-antagonist (GGPP). We were not able 
to show a difference in the protein expression of ABCA1, ABCG1 and SR-BI with or 
without GGPP-treatment. Thus, we assume that besides LXRα, also other factors may 
be involved in the regulation of the respective genes. 
Next, we asked, whether the cLDL-induced increase of the cholesterol efflux to apoA-I 
could be inhibited by probucol, a substance reported to inhibit ABCA1-mediated 
cholesterol efflux. The cholesterol efflux to apoA-I of probucol-treated THP-1 
macrophages incubated with cLDL did not differ from those without probucol treatment. 
Probucol, however, reduced the large increase in cholesterol efflux to apoA-I observed  
in cholesterol-loaded THP-1 macrophages treated with a synthetic LXR-agonist. It 
appears possible that the cLDL-induced increase of cholesterol efflux to apoA-I was 
too small to demonstrate the effect of the inhibitor. 
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In addition, we asked whether LXRα regulates the expression of ABCA1, ABCG1 and 
SR-BI not only in mature macrophages but also during THP-1 differentiation. We could 
not find any correlation between the mRNA expression of LXRα and ABCA1, ABCG1 
or SR-BI. Thus, we assume that LXRα is not involved in the expression of these genes 
during macrophage differentiation. 
To identify additional factors, which may be involved in the regulation of ABCA1, 
ABCG1 and SR-BI by modified LDL in mature macrophages, we studied the 
expression of two candidate microRNAs that are supposed to negatively regulate 
ABCA1 and SR-BI. The expression of miR-33a, which is predicted to target ABCA1, 
did not differ between THP-1 macrophages incubated with modified forms of LDL. By 
contrast, the expression of miR-223, which is predicted to target SR-BI, was decreased  
slightly when cells were incubated with both, nLDL or cLDL. This is consistent with our 
results showing that SR-BI mRNA expression was upregulated upon nLDL or cLDL 
incubation. Furthermore, miR-223 expression was decreased when THP-1 
macrophages were incubated with oxLDL or acLDL, two modified LDLs that have been 
reported to reduce SR-BI mRNA. 
Recent data show, that besides LDL, also HDL undergoes carbamylation in patients 
with CRF and it was suggested that this modification renders HDL dysfunctional. 
Therefore we studied the effect of in vitro carbamylation on HDL cholesterol acceptor 
capacity (CAC). Even after extensive carbamylation, we could not find any difference 
in the CAC between native or carbamylated HDL. 
The serum levels of cholesterol acceptors are often altered in CRF patients as 
compared to healthy individuals. Thus, we studied the CAC of serum of these patients 
and matched healthy controls. Indeed, we found a significant reduction of the CAC of 
serum of ESRD-patients on hemodialysis treatment, which could be explained in part 
by low serum apoA-I. Serum of CRF patients in earlier stages of the disease and 
without hemodialysis, however, had a slightly increased CAC as compared to controls. 
In conclusion, we could demonstrate that cLDL alters the gene expression of ABCA1, 
ABCG1 and SR-BI and thus, changes the cholesterol efflux of THP-1 macrophages. 
Furthermore, this effect may in part be mediated by LXRα but other molecules, such as 
microRNAs, may contribute. Thus, the molecular mechanisms behind the cLDL-
induced changes remain incompletely understood and need further investigation. 
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8 Zusammenfassung 
Atherosklerose ist durch Ablagerungen in der arteriellen Gefäßwand gekennzeichnet, 
welche zu medizinischen Komplikationen wie Herzinfarkt oder Schlaganfall führen 
können. Bei Patienten mit chronischem Nierenversagen (CRF) wird oft ein sehr 
rascher Verlauf der Atherosklerose beobachtet. Zusätzlich zu den traditionellen Risiko-
faktoren, weisen CRF-Patienten erhöhte Harnstoffkonzentrationen im Plasma auf, 
wodurch die Carbamylierung von Proteinen (wie zB LDL) induziert wird. 
Carbamyliertes LDL (cLDL) wird unspezifisch und unreguliert in Makrophagen 
aufgenommen, was folglich zur vermehrten Bildung von Schaumzellen führt. 
Diese Studie beschäftigt sich mit der Frage, ob dieser erhöhten unspezifischen 
Aufnahme von cLDL durch eine Erhöhung des zellulären Cholesterinefflux 
entgegenwirkt wird. Dazu untersuchten wir cLDL-induzierte Veränderungen im 
Cholesterinefflux von Makrophagen und in der Expression der Transporter, die den 
Effluxprozess vermitteln. Wir konnten nachweisen, dass Inkubation mit cLDL den 
Cholesterinefflux aus THP-1 Makrophagen zu apoA-I erhöhte. Wir konnten auch 
zeigen, dass cLDL die Expression von ABCA1, ABCG1, SR-BI, und bei höheren 
Dosen auch von LXRα, steigert. Weiters verursachte auch natives LDL (nLDL) einen 
Anstieg der SR-BI und LXRα mRNA. Um zu untersuchen, ob die von cLDL 
hervorgerufene Veränderung der Expression von ABCA1, ABCG1 und SR-BI durch 
LXRα vermittelt wird, inkubierten wir THP-1 Makrophagen mit BSA, nLDL oder cLDL, 
und mit einem LXR-Antagonisten (GGPP). Im Vergleich zur Kontrollinkubation konnten 
wir keinen Effekt von GGPP auf die Proteinexpression dieser Transporter feststellen. 
Somit nehmen wir an, dass neben LXRα auch andere Faktoren an der Regulation der 
entsprechenden Gene beteiligt sind. 
Wir untersuchten, ob die durch cLDL induzierte Steigerung des Cholesterineffluxes zu 
apoA-I durch Probucol (verhindert den Cholesterinefflux über ABCA1) verhindert 
werden kann. Dies war jedoch nicht der Fall. Dennoch war es mit Probucol möglich, 
den starken Anstieg des Cholesterinefflux zu apoA-I in cholesterinbeladenen und mit 
einem LXR-Agonisten behandelten THP-1 Makrophagen zu reduzieren. Es erscheint 
möglich, dass die Steigerung des Cholesterineffluxes von cLDL-inkubierten Zellen zu 
apoA-I zu gering ist um den Effekt des Inhibitors zu erkennen. 
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Wir prüften, ob LXRα die Expression von ABCA1, ABCG1 und SR-BI nicht nur in reifen 
Makrophagen, sondern auch während deren Differenzierung reguliert. Wir konnten 
jedoch keine Korrelation zwischen der mRNA Expression von LXRα und jener von 
ABCA1, ABCG1 oder SR-BI finden. Somit nehmen wir an, dass LXRα nicht an der 
Expression dieser Gene während der Makrophagendifferenzierung beteiligt ist. 
Um weitere Faktoren zu identifizieren, die an der Regulierung von ABCA1, ABCG1 
und SR-BI durch modifizierte LDL in reifen Makrophagen beteiligt sein könnten, unter-
suchten wir die Expression von miR-33a und miR-223, welche ABCA1 bzw. SR-BI 
negativ regulieren. In der Expression von miR-33a konnte kein Unterschied im 
Vergleich zur Kontrolle festgestellt werden, wenn Zellen mit modifizierten Formen von 
LDL inkubiert wurden. Im Gegensatz dazu verringerte sich miR-223, dessen mögliches 
Ziel SR-BI ist, in nLDL- oder cLDL-inkubierten THP-1 Makrophagen. Dieser Effekt 
korreliert damit, dass die SR-BI mRNA durch cLDL bzw. nLDL hochreguliert wurde. 
Zudem verringerte sich die Expression von miR-223 in oxLDL- oder acLDL-inkubierten 
Zellen. Beides sind modifizierte Formen von LDL, die die SR-BI mRNA reduzieren. 
Neuere Studien zeigten, dass bei CRF-Patienten neben LDL auch HDL carbamyliert 
wird und dass diese Modifizierung mit einem Verlust der HDL-Funktion einhergehen 
könnte. Aus diesem Grund untersuchten wir den Effekt von in vitro carbamyliertem 
HDL auf die Cholesterinakzeptorkapazität (CAC). Trotz extensiver Carbamylierung 
konnten wir keinen Unterschied in der CAC zwischen cHDL und nHDL nachweisen. 
Weiters sind die Cholesterinakzeptoren im Serum von CRF-Patienten häufig 
verändert. Tatsächlich konnten wir eine signifikante Reduktion der CAC von Seren von 
Dialysepatienten finden. Diese konnte zum Teil durch deren geringen Anteil von 
apoA-I im Serum erklärt werden. Serum von CRF-Patienten, die noch keine Dialyse 
benötigen, hatte hingegen eine gering erhöhte CAC.  
Mit unserer Studie konnten wir zeigen, dass cLDL die Genexpression von ABCA1, 
ABCG1 und SR-BI, und in weiterer Folge den Cholesterinefflux aus Makrophagen 
verändert. Die molekularen Mechanismen der cLDL-vermittelten Veränderungen sind 
jedoch nicht vollständig geklärt und weitere Untersuchungen sind notwendig, um die 
Rolle von cLDL in der Entstehung von Atherosklerose aufzuklären. 
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10 Supplementary Data 
 CRF ESRD on hemodialysis treatment 
 
controls (n=17) patients (n=17) controls (n=14) patients (n=14) 
Clinical characteristics     
Gender (m/f) (6/11) (6/11) (8/6) (8/6) 
Age (years) 34.9±9.3 34.6±8.6 36.0±9.6 36.7±10.2 
BMI 22.3±2.5 22.7±3.5 24.0±3.1 25.3±4.8 
KDOQI (3/4/5) (n) - 6/8/3 - -/-/14 
Creatinine (mg/dl) 0.8±0.1 3.8±3.0*** 0.9±0.2 7.7±4.1*** 
Serum lipids     
Cholesterol (mg/dl) 171.8±29.3 186.7±45.7 188.0±38.0 169.7±51.7 
Triglycerides (mg/dl) 83.3±49.4 112.4±46.7 92.4±55.5 126.2±69.1 
HDL (mg/dl) 49.5±15.9 42.0±12.9 53.2±14.1 36.8±9.3** 
LDL (mg/dl) 105.6±31.9 122.3±41.2 116.3±32.8 107.7±47.6 
Free Cholesterol (mg/dl) 50.2±8.2 55.7±13.3 54.4±11.2 53.4±18.1 
Phospholipids (mg/dl) 216.1±26.9 210.9±40.1 229.6±35.9 213.1±65.2 
Free fatty acids (mmol/l) 0.5±0.2 0.5±0.3 0.4±0.1 1.1±0.8** 
Serum apoproteins     
Apo A-I (mg/dl) 155.4±27.9 145.1±32.0 166.6±29.8 132.4±27.0** 
Apo A-II (mg/dl) 35.5±4.9 34.2±7.8 41.4±7.3 31.0±5.8*** 
Apo B (mg/dl) 71.3±22.5 88.0±26.4 76.6±27.1 68.1±18.4 
Apo C-II (mg/dl) 2.9±1.5 3.8±1.6 3.2±1.5 4.5±2.9 
Apo C-III (mg/dl) 7.6±2.5 11.2±7.1 11.1±4.4 17.7±11.0 
Apo C-II/Apo C-III 0.4±0.2 0.4±0.2 0.3±0.1 0.3±0.1 
Apo E (mg/dl) 7.9±1.6 8.9±1.9 8.9±2.8 14.1±14.1 
Lp (a) (mg/dl) 10.2±9.5 29.4±31.3* 13.8±12.5 19.5±22.3 
Table 15: Clinical characteristics, serum lipids and apoproteins of the study patients and controls 
(mean ± SD, * p < 0.05, ** p < 0.01, *** p < 0001, patients vs. controls 
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